NO326776B1 - CHK1-inhibitorer, farmasoytiske sammensetninger samt anvendelser derav - Google Patents
CHK1-inhibitorer, farmasoytiske sammensetninger samt anvendelser derav Download PDFInfo
- Publication number
- NO326776B1 NO326776B1 NO20033858A NO20033858A NO326776B1 NO 326776 B1 NO326776 B1 NO 326776B1 NO 20033858 A NO20033858 A NO 20033858A NO 20033858 A NO20033858 A NO 20033858A NO 326776 B1 NO326776 B1 NO 326776B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- methyl
- mmol
- pyrazin
- mhz
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 239000003112 inhibitor Substances 0.000 title description 39
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 title description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 452
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 69
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 73
- -1 N(R<7>)2 Chemical group 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 38
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical group 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000001301 oxygen Chemical group 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 219
- 230000005778 DNA damage Effects 0.000 abstract description 23
- 231100000277 DNA damage Toxicity 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 14
- 230000007547 defect Effects 0.000 abstract description 8
- 230000004543 DNA replication Effects 0.000 abstract description 7
- 230000032823 cell division Effects 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 230000024321 chromosome segregation Effects 0.000 abstract description 2
- 150000003672 ureas Chemical class 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 335
- 239000000243 solution Substances 0.000 description 267
- 238000005160 1H NMR spectroscopy Methods 0.000 description 259
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 201
- 239000011541 reaction mixture Substances 0.000 description 173
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 137
- 235000019439 ethyl acetate Nutrition 0.000 description 132
- 239000007787 solid Substances 0.000 description 97
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 94
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 90
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 85
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 82
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 79
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 66
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 64
- 239000000047 product Substances 0.000 description 62
- 238000003756 stirring Methods 0.000 description 60
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 44
- 239000000203 mixture Substances 0.000 description 44
- 239000000725 suspension Substances 0.000 description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 239000002244 precipitate Substances 0.000 description 42
- 239000000460 chlorine Substances 0.000 description 41
- 101150006084 CHKB gene Proteins 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 239000004202 carbamide Substances 0.000 description 39
- 239000012074 organic phase Substances 0.000 description 38
- 230000002829 reductive effect Effects 0.000 description 37
- 239000003921 oil Substances 0.000 description 36
- 235000019198 oils Nutrition 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 229910000029 sodium carbonate Inorganic materials 0.000 description 33
- 238000001914 filtration Methods 0.000 description 31
- 239000012043 crude product Substances 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 230000005855 radiation Effects 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 101150113535 chek1 gene Proteins 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 19
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 18
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 238000006751 Mitsunobu reaction Methods 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 17
- 238000010511 deprotection reaction Methods 0.000 description 17
- 230000005865 ionizing radiation Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002246 antineoplastic agent Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229910052708 sodium Inorganic materials 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 108010009583 Transforming Growth Factors Proteins 0.000 description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 11
- 101150012716 CDK1 gene Proteins 0.000 description 11
- 230000012746 DNA damage checkpoint Effects 0.000 description 11
- 239000012623 DNA damaging agent Substances 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 11
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 229960002949 fluorouracil Drugs 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 11
- 231100001274 therapeutic index Toxicity 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000011278 mitosis Effects 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 230000012820 cell cycle checkpoint Effects 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 229940126864 fibroblast growth factor Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 7
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 6
- ZNQOALAKPLGUPH-UHFFFAOYSA-N 5-methylpyrazin-2-amine Chemical compound CC1=CN=C(N)C=N1 ZNQOALAKPLGUPH-UHFFFAOYSA-N 0.000 description 6
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000025084 cell cycle arrest Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 230000005670 electromagnetic radiation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003365 glass fiber Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- LYWVGZVVVRAMAU-UHFFFAOYSA-N 1-[4-(aminomethyl)-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC(CN)=CC=C1NC(=O)NC1=CN=C(C)C=N1 LYWVGZVVVRAMAU-UHFFFAOYSA-N 0.000 description 5
- ZDMISTLJKQDGTB-UHFFFAOYSA-N 4-(bromomethyl)-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(CBr)=CC=C1[N+]([O-])=O ZDMISTLJKQDGTB-UHFFFAOYSA-N 0.000 description 5
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 5
- 230000037060 G2 phase arrest Effects 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 5
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- AADYWCBPJZAJNU-UHFFFAOYSA-N (3-methoxy-4-nitrophenyl)methanol Chemical compound COC1=CC(CO)=CC=C1[N+]([O-])=O AADYWCBPJZAJNU-UHFFFAOYSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- ICPRYRZRCCHGKS-UHFFFAOYSA-N 1-(5-amino-2-methoxyphenyl)-3-pyrazin-2-ylurea Chemical compound COC1=CC=C(N)C=C1NC(=O)NC1=CN=CC=N1 ICPRYRZRCCHGKS-UHFFFAOYSA-N 0.000 description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 4
- JTPXVCKCLBROOJ-UHFFFAOYSA-N 2-amino-6-chloropyrazine Chemical compound NC1=CN=CC(Cl)=N1 JTPXVCKCLBROOJ-UHFFFAOYSA-N 0.000 description 4
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 4
- GIJIEBQDSPHDIP-UHFFFAOYSA-N 3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)NC1=CN=C(C)C=N1 GIJIEBQDSPHDIP-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- JSXYKMRDXPBXRD-UHFFFAOYSA-N 5-methylpyrazine-2-carbonyl azide Chemical compound CC1=CN=C(C(=O)N=[N+]=[N-])C=N1 JSXYKMRDXPBXRD-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- 102000002427 Cyclin B Human genes 0.000 description 4
- 108010068150 Cyclin B Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000013736 caramel Nutrition 0.000 description 4
- 230000006369 cell cycle progression Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- QVDWKLDUBSJEOG-UHFFFAOYSA-N methyl 3-amino-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(N)=C1 QVDWKLDUBSJEOG-UHFFFAOYSA-N 0.000 description 4
- GUFQJJRSGPHGBJ-UHFFFAOYSA-N methyl 4-methoxy-3-[(4-nitrophenoxy)carbonylamino]benzoate Chemical compound COC(=O)C1=CC=C(OC)C(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 GUFQJJRSGPHGBJ-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 230000003007 single stranded DNA break Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- UGXQXVDTGJCQHR-UHFFFAOYSA-N (1-methylpiperidin-3-yl)methanol Chemical compound CN1CCCC(CO)C1 UGXQXVDTGJCQHR-UHFFFAOYSA-N 0.000 description 3
- QHFKWIKCUHNXAU-UHFFFAOYSA-N (4-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 QHFKWIKCUHNXAU-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 3
- SRRCSRKEXMQOID-UHFFFAOYSA-N 1-(4-amino-2-methoxyphenyl)-3-pyrazin-2-ylurea Chemical compound COC1=CC(N)=CC=C1NC(=O)NC1=CN=CC=N1 SRRCSRKEXMQOID-UHFFFAOYSA-N 0.000 description 3
- HYAHBRUZNJIAAO-UHFFFAOYSA-N 1-(5-benzoylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C(=O)C=2C=CC=CC=2)C=N1 HYAHBRUZNJIAAO-UHFFFAOYSA-N 0.000 description 3
- WJILDCCNAOOEGU-UHFFFAOYSA-N 1-[4-[[benzyl(methyl)amino]methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CN(C)CC1=CC=CC=C1 WJILDCCNAOOEGU-UHFFFAOYSA-N 0.000 description 3
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 3
- IDOHLSFNBKNRRJ-UHFFFAOYSA-N 2-isocyanato-1-methoxy-4-methylbenzene Chemical compound COC1=CC=C(C)C=C1N=C=O IDOHLSFNBKNRRJ-UHFFFAOYSA-N 0.000 description 3
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 3
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 3
- SMLJERTWGUYNSP-UHFFFAOYSA-N 3-bromo-5-phenylpyrazin-2-amine Chemical compound N1=C(Br)C(N)=NC=C1C1=CC=CC=C1 SMLJERTWGUYNSP-UHFFFAOYSA-N 0.000 description 3
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 3
- BYIKUPJPRGPSHV-UHFFFAOYSA-N 4-[[benzyl(methyl)amino]methyl]-2-methoxyaniline Chemical compound C1=C(N)C(OC)=CC(CN(C)CC=2C=CC=CC=2)=C1 BYIKUPJPRGPSHV-UHFFFAOYSA-N 0.000 description 3
- VXVBDEIJJJMHBW-UHFFFAOYSA-N 4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1NC(=O)NC1=CN=CC=N1 VXVBDEIJJJMHBW-UHFFFAOYSA-N 0.000 description 3
- LTWBZUZTTUVPIM-UHFFFAOYSA-N 5,6-diphenyl-1h-pyrazin-2-one Chemical compound C=1C=CC=CC=1C=1NC(=O)C=NC=1C1=CC=CC=C1 LTWBZUZTTUVPIM-UHFFFAOYSA-N 0.000 description 3
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 3
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 3
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 3
- VGKOARVVEXZTPU-UHFFFAOYSA-N n-methylpyrazin-2-amine Chemical compound CNC1=CN=CC=N1 VGKOARVVEXZTPU-UHFFFAOYSA-N 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940080469 phosphocellulose Drugs 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- BHUOKTAFBOQMBL-UHFFFAOYSA-N quinoxaline-2-carbonyl azide Chemical compound C1=CC=CC2=NC(C(=O)N=[N+]=[N-])=CN=C21 BHUOKTAFBOQMBL-UHFFFAOYSA-N 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000000649 small cell carcinoma Diseases 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- WVQYSZHSAWUZMS-UHFFFAOYSA-N tert-butyl n-(2-hydroxy-5-methylphenyl)carbamate Chemical compound CC1=CC=C(O)C(NC(=O)OC(C)(C)C)=C1 WVQYSZHSAWUZMS-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KNUKUWNSGVICSX-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)methanamine Chemical compound C1CC(CN)CCN1CC1=CC=CC=C1 KNUKUWNSGVICSX-UHFFFAOYSA-N 0.000 description 2
- GTRJGGQNXFHOFM-UHFFFAOYSA-N (1-ethyl-3,4-dihydro-2h-quinolin-3-yl)methanol Chemical compound C1=CC=C2N(CC)CC(CO)CC2=C1 GTRJGGQNXFHOFM-UHFFFAOYSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- HBVNLKQGRZPGRP-LLVKDONJSA-N (3r)-1-benzylpyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-LLVKDONJSA-N 0.000 description 2
- XQBNUZCWBALDMP-NSHDSACASA-N (3s)-1-[(4-fluorophenyl)methyl]pyrrolidin-3-amine Chemical compound C1[C@@H](N)CCN1CC1=CC=C(F)C=C1 XQBNUZCWBALDMP-NSHDSACASA-N 0.000 description 2
- PWWRXANDKQBKRW-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-3-ylmethanol Chemical compound C1=CC=C2CC(CO)CNC2=C1 PWWRXANDKQBKRW-UHFFFAOYSA-N 0.000 description 2
- UBAYDDDQLQMWLF-UHFFFAOYSA-N 1-(2-methoxy-4-nitrophenyl)-3-pyrazin-2-ylurea Chemical compound COC1=CC([N+]([O-])=O)=CC=C1NC(=O)NC1=CN=CC=N1 UBAYDDDQLQMWLF-UHFFFAOYSA-N 0.000 description 2
- PNFMSAHOBWUJRY-UHFFFAOYSA-N 1-(2-methoxy-5-nitrophenyl)-3-pyrazin-2-ylurea Chemical compound COC1=CC=C([N+]([O-])=O)C=C1NC(=O)NC1=CN=CC=N1 PNFMSAHOBWUJRY-UHFFFAOYSA-N 0.000 description 2
- OIINFIJOJMDSJR-UHFFFAOYSA-N 1-(3-methoxy-4-nitrophenyl)-n,n-dimethylmethanamine Chemical compound COC1=CC(CN(C)C)=CC=C1[N+]([O-])=O OIINFIJOJMDSJR-UHFFFAOYSA-N 0.000 description 2
- RWEKQNRDUQKRCJ-UHFFFAOYSA-N 1-(5-bromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(Br)C=N1 RWEKQNRDUQKRCJ-UHFFFAOYSA-N 0.000 description 2
- VOIAFHMLADQCCF-UHFFFAOYSA-N 1-(6-azidopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=CC(N=[N+]=[N-])=N1 VOIAFHMLADQCCF-UHFFFAOYSA-N 0.000 description 2
- NEVGICHSHFFCFG-UHFFFAOYSA-N 1-[2-[(1-ethyl-3,4-dihydro-2h-quinolin-3-yl)methoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1C2=CC=CC=C2N(CC)CC1COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 NEVGICHSHFFCFG-UHFFFAOYSA-N 0.000 description 2
- LMDPDSOLFYAGEV-UHFFFAOYSA-N 1-[2-[3-(dimethylamino)propoxy]-5-methylphenyl]-3-pyrazin-2-ylurea Chemical compound CN(C)CCCOC1=CC=C(C)C=C1NC(=O)NC1=CN=CC=N1 LMDPDSOLFYAGEV-UHFFFAOYSA-N 0.000 description 2
- YHNCCYLEHDEQGG-UHFFFAOYSA-N 1-[2-methoxy-4-(methylaminomethyl)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC(CNC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 YHNCCYLEHDEQGG-UHFFFAOYSA-N 0.000 description 2
- PBJBQLVPWOBINS-UHFFFAOYSA-N 1-[2-methoxy-4-(phenylmethoxymethyl)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1COCC1=CC=CC=C1 PBJBQLVPWOBINS-UHFFFAOYSA-N 0.000 description 2
- BZYMTLWCKVNOFZ-UHFFFAOYSA-N 1-[5-[(1,3-dioxoisoindol-2-yl)methyl]pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC(N=C1)=CN=C1CN1C(=O)C2=CC=CC=C2C1=O BZYMTLWCKVNOFZ-UHFFFAOYSA-N 0.000 description 2
- BERTYYBZMZHDPY-UHFFFAOYSA-N 1-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-quinoxalin-2-ylurea Chemical compound C=1N=C2C=CC=CC2=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CC=CN=C1 BERTYYBZMZHDPY-UHFFFAOYSA-N 0.000 description 2
- HDMVAVYJHTYDLW-UHFFFAOYSA-N 1-[5-methyl-2-[(1-methylpiperidin-3-yl)methoxy]phenyl]-3-quinoxalin-2-ylurea Chemical compound C1N(C)CCCC1COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C=CC=C2)C2=N1 HDMVAVYJHTYDLW-UHFFFAOYSA-N 0.000 description 2
- HBVNLKQGRZPGRP-UHFFFAOYSA-N 1-benzylpyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-UHFFFAOYSA-N 0.000 description 2
- NWESJZZPAJGHRZ-UHFFFAOYSA-N 1-chloro-4-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Cl)C([N+]([O-])=O)=C1 NWESJZZPAJGHRZ-UHFFFAOYSA-N 0.000 description 2
- UCOSRTUSVXHIMK-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanamine Chemical compound C1=CC=C2NC(CN)=NC2=C1 UCOSRTUSVXHIMK-UHFFFAOYSA-N 0.000 description 2
- CHDAHGDVWCVSOA-UHFFFAOYSA-N 2-(4-methyl-2-nitrophenoxy)pyridine Chemical compound [O-][N+](=O)C1=CC(C)=CC=C1OC1=CC=CC=N1 CHDAHGDVWCVSOA-UHFFFAOYSA-N 0.000 description 2
- HEKKXNNVIAECAN-UHFFFAOYSA-N 2-(benzenesulfonyl)ethanamine Chemical compound NCCS(=O)(=O)C1=CC=CC=C1 HEKKXNNVIAECAN-UHFFFAOYSA-N 0.000 description 2
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- FRRWGQLBDQLWBE-UHFFFAOYSA-N 2-[(1-ethyl-3,4-dihydro-2h-quinolin-3-yl)methoxy]-5-methylaniline Chemical compound C1C2=CC=CC=C2N(CC)CC1COC1=CC=C(C)C=C1N FRRWGQLBDQLWBE-UHFFFAOYSA-N 0.000 description 2
- KSHSBSFLRWWGHU-UHFFFAOYSA-N 2-[(3-methoxy-4-nitrophenyl)methyl]isoindole-1,3-dione Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CN2C(C3=CC=CC=C3C2=O)=O)=C1 KSHSBSFLRWWGHU-UHFFFAOYSA-N 0.000 description 2
- ZAPOIXDHXABOMI-UHFFFAOYSA-N 2-[(4-amino-3-methoxyphenyl)methyl]isoindole-1,3-dione Chemical compound C1=C(N)C(OC)=CC(CN2C(C3=CC=CC=C3C2=O)=O)=C1 ZAPOIXDHXABOMI-UHFFFAOYSA-N 0.000 description 2
- PYKAQIPAYYODTG-UHFFFAOYSA-N 2-[(5-aminopyrazin-2-yl)methyl]isoindole-1,3-dione Chemical compound C1=NC(N)=CN=C1CN1C(=O)C2=CC=CC=C2C1=O PYKAQIPAYYODTG-UHFFFAOYSA-N 0.000 description 2
- FBOCALVFRHALTF-UHFFFAOYSA-N 2-[3-(dimethylamino)propoxy]-5-methylaniline Chemical compound CN(C)CCCOC1=CC=C(C)C=C1N FBOCALVFRHALTF-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- ZMXYNJXDULEQCK-UHFFFAOYSA-N 2-amino-p-cresol Chemical compound CC1=CC=C(O)C(N)=C1 ZMXYNJXDULEQCK-UHFFFAOYSA-N 0.000 description 2
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 2
- UFXWQENCTLHNQJ-UHFFFAOYSA-N 2-methoxy-4-(methoxymethyl)-1-nitrobenzene Chemical compound COCC1=CC=C([N+]([O-])=O)C(OC)=C1 UFXWQENCTLHNQJ-UHFFFAOYSA-N 0.000 description 2
- FAMORTPTYCYSQW-UHFFFAOYSA-N 2-methoxy-4-(methoxymethyl)aniline Chemical compound COCC1=CC=C(N)C(OC)=C1 FAMORTPTYCYSQW-UHFFFAOYSA-N 0.000 description 2
- IDLHTECVNDEOIY-UHFFFAOYSA-N 2-pyridin-4-ylethanamine Chemical compound NCCC1=CC=NC=C1 IDLHTECVNDEOIY-UHFFFAOYSA-N 0.000 description 2
- HYZYHVUIWRRMEZ-UHFFFAOYSA-N 3,6-dimethylpyrazin-2-amine Chemical compound CC1=CN=C(C)C(N)=N1 HYZYHVUIWRRMEZ-UHFFFAOYSA-N 0.000 description 2
- PEVVFPQOAHCYML-UHFFFAOYSA-N 3-(4-methyl-2-nitrophenoxy)pyridine Chemical compound [O-][N+](=O)C1=CC(C)=CC=C1OC1=CC=CN=C1 PEVVFPQOAHCYML-UHFFFAOYSA-N 0.000 description 2
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 2
- FCTLDQFUKJKXIH-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzoic acid Chemical compound CN(C)CCCOC1=CC(C(O)=O)=CC=C1NC(=O)NC1=CN=C(C)C=N1 FCTLDQFUKJKXIH-UHFFFAOYSA-N 0.000 description 2
- SNSWHGVBOXMHAS-UHFFFAOYSA-N 3-azido-2,5-dimethylpyrazine Chemical compound CC1=CN=C(C)C(N=[N+]=[N-])=N1 SNSWHGVBOXMHAS-UHFFFAOYSA-N 0.000 description 2
- FRILHWMPPIFUAZ-UHFFFAOYSA-N 3-chloro-n-[3-methoxy-4-(pyrazin-2-ylcarbamoylamino)phenyl]propanamide Chemical compound COC1=CC(NC(=O)CCCl)=CC=C1NC(=O)NC1=CN=CC=N1 FRILHWMPPIFUAZ-UHFFFAOYSA-N 0.000 description 2
- HPLDNFXIKKYGLZ-UHFFFAOYSA-N 3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)NC1=CN=CC=N1 HPLDNFXIKKYGLZ-UHFFFAOYSA-N 0.000 description 2
- ACYYKUSBZUVGRD-UHFFFAOYSA-N 3-methoxy-4-[[5-(trifluoromethyl)pyrazin-2-yl]carbamoylamino]benzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)NC1=CN=C(C(F)(F)F)C=N1 ACYYKUSBZUVGRD-UHFFFAOYSA-N 0.000 description 2
- CCPUOOUROHGAOD-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC=C1[N+]([O-])=O CCPUOOUROHGAOD-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- GTLJWXVJOCJGQZ-UHFFFAOYSA-N 4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzoic acid Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(C(O)=O)C=C1OCC1=CC=CN=C1 GTLJWXVJOCJGQZ-UHFFFAOYSA-N 0.000 description 2
- PPHOFIWOEROCEX-UHFFFAOYSA-N 4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(trifluoromethoxy)benzoic acid Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(C(O)=O)C=C1OC(F)(F)F PPHOFIWOEROCEX-UHFFFAOYSA-N 0.000 description 2
- DPQIBVKVVGXAPI-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-2-methoxyaniline Chemical compound COC1=CC(CN(C)C)=CC=C1N DPQIBVKVVGXAPI-UHFFFAOYSA-N 0.000 description 2
- JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 2
- JTPCVJQUFYRJES-UHFFFAOYSA-N 5,6-dimethylpyrazin-2-amine Chemical compound CC1=NC=C(N)N=C1C JTPCVJQUFYRJES-UHFFFAOYSA-N 0.000 description 2
- BOIRYLPSITXMRA-UHFFFAOYSA-N 5,6-diphenylpyrazin-2-amine Chemical compound C=1C=CC=CC=1C1=NC(N)=CN=C1C1=CC=CC=C1 BOIRYLPSITXMRA-UHFFFAOYSA-N 0.000 description 2
- VYANAPRTDDQFJY-UHFFFAOYSA-N 5-aminopyrazine-2-carbonitrile Chemical compound NC1=CN=C(C#N)C=N1 VYANAPRTDDQFJY-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- PMBFOUDQIHUELM-UHFFFAOYSA-N 5-azido-2,3-diphenylpyrazine Chemical compound C=1C=CC=CC=1C1=NC(N=[N+]=[N-])=CN=C1C1=CC=CC=C1 PMBFOUDQIHUELM-UHFFFAOYSA-N 0.000 description 2
- OOOGJKOYWSKJFC-UHFFFAOYSA-N 5-benzoylpyrazine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CN=C1C(=O)C1=CC=CC=C1 OOOGJKOYWSKJFC-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- VUGNCPVAXWZTOL-UHFFFAOYSA-N 5-chloro-2,3-diphenylpyrazine Chemical compound C=1C=CC=CC=1C1=NC(Cl)=CN=C1C1=CC=CC=C1 VUGNCPVAXWZTOL-UHFFFAOYSA-N 0.000 description 2
- ITXMRWYSIZIJDG-UHFFFAOYSA-N 5-ethylpyrazin-2-amine Chemical compound CCC1=CN=C(N)C=N1 ITXMRWYSIZIJDG-UHFFFAOYSA-N 0.000 description 2
- RJIAPNNMHOGCCE-UHFFFAOYSA-N 5-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]-2-(trifluoromethyl)benzoic acid Chemical compound COC1=CC(C(O)=O)=C(C(F)(F)F)C=C1NC(=O)NC1=CN=C(C)C=N1 RJIAPNNMHOGCCE-UHFFFAOYSA-N 0.000 description 2
- XIUAFNYUTGHTST-UHFFFAOYSA-N 5-methyl-2-[(1-methylpiperidin-3-yl)methoxy]aniline Chemical compound C1N(C)CCCC1COC1=CC=C(C)C=C1N XIUAFNYUTGHTST-UHFFFAOYSA-N 0.000 description 2
- KJAKXVBZQBPPOB-UHFFFAOYSA-N 5-phenylpyrazin-2-amine Chemical compound C1=NC(N)=CN=C1C1=CC=CC=C1 KJAKXVBZQBPPOB-UHFFFAOYSA-N 0.000 description 2
- YGFNVCMGUHJLRU-UHFFFAOYSA-N 6-methoxypyrazin-2-amine Chemical compound COC1=CN=CC(N)=N1 YGFNVCMGUHJLRU-UHFFFAOYSA-N 0.000 description 2
- ZSRANPPJBKMMSP-UHFFFAOYSA-N 6-phenylmethoxypyrazin-2-amine Chemical compound NC1=CN=CC(OCC=2C=CC=CC=2)=N1 ZSRANPPJBKMMSP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008122 Casein Kinase I Human genes 0.000 description 2
- 108010049812 Casein Kinase I Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 2
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 description 2
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101500026845 Rattus norvegicus C3-beta-c Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- ULUFEHXIYTVHDD-INIZCTEOSA-N [(3s)-1-benzylpyrrolidin-3-yl] 3-methoxy-4-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=C1 ULUFEHXIYTVHDD-INIZCTEOSA-N 0.000 description 2
- BPLGJCBAHOTTEP-INIZCTEOSA-N [(3s)-1-benzylpyrrolidin-3-yl] 4-amino-3-methoxybenzoate Chemical compound C1=C(N)C(OC)=CC(C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=C1 BPLGJCBAHOTTEP-INIZCTEOSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000011226 adjuvant chemotherapy Methods 0.000 description 2
- 238000011353 adjuvant radiotherapy Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- LZRDCBPCLLOIQK-UHFFFAOYSA-N benzyl 3-[(2-amino-4-methylphenoxy)methyl]-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound NC1=CC(C)=CC=C1OCC1CC2=CC=CC=C2N(C(=O)OCC=2C=CC=CC=2)C1 LZRDCBPCLLOIQK-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- QDWJUBJKEHXSMT-UHFFFAOYSA-N boranylidynenickel Chemical compound [Ni]#B QDWJUBJKEHXSMT-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- ARAIDTMLOPPTPE-UHFFFAOYSA-N methyl 1,2,3,4-tetrahydroquinoline-3-carboxylate Chemical compound C1=CC=C2CC(C(=O)OC)CNC2=C1 ARAIDTMLOPPTPE-UHFFFAOYSA-N 0.000 description 2
- OCZOEUGJBGPVDC-UHFFFAOYSA-N methyl 3-[3-(dimethylamino)propoxy]-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(OCCCN(C)C)=C1 OCZOEUGJBGPVDC-UHFFFAOYSA-N 0.000 description 2
- UEGCRFNWTGYVKX-UHFFFAOYSA-N methyl 3-hydroxy-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(O)=C1 UEGCRFNWTGYVKX-UHFFFAOYSA-N 0.000 description 2
- ZEMLSASYVACBHO-UHFFFAOYSA-N methyl 3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=CC=N1 ZEMLSASYVACBHO-UHFFFAOYSA-N 0.000 description 2
- ACYFJCVPXJZJRP-UHFFFAOYSA-N methyl 3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 ACYFJCVPXJZJRP-UHFFFAOYSA-N 0.000 description 2
- KMGCYUMIWKTCAN-UHFFFAOYSA-N methyl 3-methoxy-4-[[5-(trifluoromethyl)pyrazin-2-yl]carbamoylamino]benzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=C(C(F)(F)F)C=N1 KMGCYUMIWKTCAN-UHFFFAOYSA-N 0.000 description 2
- MKBCMBLBNUKICE-UHFFFAOYSA-N methyl 4-[(4-nitrophenoxy)carbonylamino]-3-(trifluoromethoxy)benzoate Chemical compound FC(F)(F)OC1=CC(C(=O)OC)=CC=C1NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 MKBCMBLBNUKICE-UHFFFAOYSA-N 0.000 description 2
- XDTCLUFSJMXNRH-UHFFFAOYSA-N methyl 4-amino-3-(pyridin-3-ylmethoxy)benzoate Chemical compound COC(=O)C1=CC=C(N)C(OCC=2C=NC=CC=2)=C1 XDTCLUFSJMXNRH-UHFFFAOYSA-N 0.000 description 2
- DBITVIUWKCMANX-UHFFFAOYSA-N methyl 4-amino-3-[3-(dimethylamino)propoxy]benzoate Chemical compound COC(=O)C1=CC=C(N)C(OCCCN(C)C)=C1 DBITVIUWKCMANX-UHFFFAOYSA-N 0.000 description 2
- XWIRJDBEVKFRIH-UHFFFAOYSA-N methyl 4-amino-5-methoxy-2-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(OC)=C(N)C=C1C(F)(F)F XWIRJDBEVKFRIH-UHFFFAOYSA-N 0.000 description 2
- POVOMWVBEBGAGO-UHFFFAOYSA-N methyl 4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzoate Chemical compound COC(=O)C1=CC=C(OC)C(NC(=O)NC=2N=CC=NC=2)=C1 POVOMWVBEBGAGO-UHFFFAOYSA-N 0.000 description 2
- HHCZAJITVOLHEN-UHFFFAOYSA-N methyl 4-nitro-3-(pyridin-3-ylmethoxy)benzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(OCC=2C=NC=CC=2)=C1 HHCZAJITVOLHEN-UHFFFAOYSA-N 0.000 description 2
- WHGYNKONBHHGML-UHFFFAOYSA-N methyl 5-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]-2-(trifluoromethyl)benzoate Chemical compound C1=C(C(F)(F)F)C(C(=O)OC)=CC(OC)=C1NC(=O)NC1=CN=C(C)C=N1 WHGYNKONBHHGML-UHFFFAOYSA-N 0.000 description 2
- CWRATHCADZOYAT-UHFFFAOYSA-N methyl quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)OC)=CN=C21 CWRATHCADZOYAT-UHFFFAOYSA-N 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- XSYGGOVDKYKDDF-UHFFFAOYSA-N n-[(1-benzylpiperidin-4-yl)methyl]-3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound COC1=CC(C(=O)NCC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 XSYGGOVDKYKDDF-UHFFFAOYSA-N 0.000 description 2
- LHJBMZSNWFHEOP-UHFFFAOYSA-N n-[(3-methoxy-4-nitrophenyl)methyl]-1-phenylmethanamine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CNCC=2C=CC=CC=2)=C1 LHJBMZSNWFHEOP-UHFFFAOYSA-N 0.000 description 2
- NXGILOBXMSIPKO-UHFFFAOYSA-N n-[(3-methoxy-4-nitrophenyl)methyl]-n-methyl-1-phenylmethanamine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CN(C)CC=2C=CC=CC=2)=C1 NXGILOBXMSIPKO-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229950006344 nocodazole Drugs 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- YOWAEZWWQFSEJD-UHFFFAOYSA-N quinoxalin-2-amine Chemical compound C1=CC=CC2=NC(N)=CN=C21 YOWAEZWWQFSEJD-UHFFFAOYSA-N 0.000 description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000034408 response to ionizing radiation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 2
- FGAZCKUQQRDXOX-UHFFFAOYSA-N tert-butyl n-(5-methylpyrazin-2-yl)carbamate Chemical compound CC1=CN=C(NC(=O)OC(C)(C)C)C=N1 FGAZCKUQQRDXOX-UHFFFAOYSA-N 0.000 description 2
- NFVJHDOOYMUMMF-UHFFFAOYSA-N tert-butyl n-[(3-methoxy-4-nitrophenyl)methyl]-n-methylcarbamate Chemical compound COC1=CC(CN(C)C(=O)OC(C)(C)C)=CC=C1[N+]([O-])=O NFVJHDOOYMUMMF-UHFFFAOYSA-N 0.000 description 2
- VUCZZAHQRXHDSZ-AWEZNQCLSA-N tert-butyl n-[(3s)-1-[(4-fluorophenyl)methyl]pyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1CC1=CC=C(F)C=C1 VUCZZAHQRXHDSZ-AWEZNQCLSA-N 0.000 description 2
- CRYHJOFLWGDFBT-UHFFFAOYSA-N tert-butyl n-[(4-amino-3-methoxyphenyl)methyl]-n-methylcarbamate Chemical compound COC1=CC(CN(C)C(=O)OC(C)(C)C)=CC=C1N CRYHJOFLWGDFBT-UHFFFAOYSA-N 0.000 description 2
- QTTFYKBSFSZPGL-UHFFFAOYSA-N tert-butyl n-[2-[(1-ethyl-3,4-dihydro-2h-quinolin-3-yl)methoxy]-5-methylphenyl]carbamate Chemical compound C1C2=CC=CC=C2N(CC)CC1COC1=CC=C(C)C=C1NC(=O)OC(C)(C)C QTTFYKBSFSZPGL-UHFFFAOYSA-N 0.000 description 2
- BVSTWYZETGXVPZ-UHFFFAOYSA-N tert-butyl n-[2-[3-(dimethylamino)propoxy]-5-methylphenyl]carbamate Chemical compound CN(C)CCCOC1=CC=C(C)C=C1NC(=O)OC(C)(C)C BVSTWYZETGXVPZ-UHFFFAOYSA-N 0.000 description 2
- BAUHWEHZBJUBSM-UHFFFAOYSA-N tert-butyl n-[5-methyl-2-(1,2,3,4-tetrahydroquinolin-3-ylmethoxy)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(C)=CC=C1OCC1CC2=CC=CC=C2NC1 BAUHWEHZBJUBSM-UHFFFAOYSA-N 0.000 description 2
- WANHFLFSUKQGLA-UHFFFAOYSA-N tert-butyl n-benzyl-n-[(3-methoxy-4-nitrophenyl)methyl]carbamate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CN(CC=2C=CC=CC=2)C(=O)OC(C)(C)C)=C1 WANHFLFSUKQGLA-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- KJZLJGZZDNGGCA-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanol Chemical compound CN1CCC(CO)CC1 KJZLJGZZDNGGCA-UHFFFAOYSA-N 0.000 description 1
- NPWMWLAPRVMNBN-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl)methanol Chemical compound CN1CCC(CO)C1 NPWMWLAPRVMNBN-UHFFFAOYSA-N 0.000 description 1
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- NUOYJPPISCCYDH-BYPYZUCNSA-N (2s)-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carbonyl chloride Chemical compound FC(F)(F)C(=O)N1CCC[C@H]1C(Cl)=O NUOYJPPISCCYDH-BYPYZUCNSA-N 0.000 description 1
- CMXCJXBSBFNWAT-LBPRGKRZSA-N (2s)-n-[4-methoxy-3-(pyrazin-2-ylcarbamoylamino)phenyl]pyrrolidine-2-carboxamide Chemical compound C1=C(NC(=O)NC=2N=CC=NC=2)C(OC)=CC=C1NC(=O)[C@@H]1CCCN1 CMXCJXBSBFNWAT-LBPRGKRZSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- GMXRYOASLQUMPP-MRVPVSSYSA-N (3r)-1-(thiophen-2-ylmethyl)pyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1CC1=CC=CS1 GMXRYOASLQUMPP-MRVPVSSYSA-N 0.000 description 1
- NXILIHONWRXHFA-MRVPVSSYSA-N (3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](C(O)=O)C1 NXILIHONWRXHFA-MRVPVSSYSA-N 0.000 description 1
- UNHOPMIDKWXFMF-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-amine Chemical compound CN1CC[C@@H](N)C1 UNHOPMIDKWXFMF-RXMQYKEDSA-N 0.000 description 1
- NXILIHONWRXHFA-QMMMGPOBSA-N (3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](C(O)=O)C1 NXILIHONWRXHFA-QMMMGPOBSA-N 0.000 description 1
- HBVNLKQGRZPGRP-NSHDSACASA-N (3s)-1-benzylpyrrolidin-3-amine Chemical compound C1[C@@H](N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-NSHDSACASA-N 0.000 description 1
- YQMXOIAIYXXXEE-NSHDSACASA-N (3s)-1-benzylpyrrolidin-3-ol Chemical compound C1[C@@H](O)CCN1CC1=CC=CC=C1 YQMXOIAIYXXXEE-NSHDSACASA-N 0.000 description 1
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- KCGZGJOBKAXVSU-UHFFFAOYSA-N (4-iodophenyl)methanamine Chemical compound NCC1=CC=C(I)C=C1 KCGZGJOBKAXVSU-UHFFFAOYSA-N 0.000 description 1
- DJCJOWDAAZEMCI-UHFFFAOYSA-N (6-methylpyridin-3-yl)methanol Chemical compound CC1=CC=C(CO)C=N1 DJCJOWDAAZEMCI-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JGVZJRHAZOBPMW-UHFFFAOYSA-N 1,3-bis(dimethylamino)propan-2-ol Chemical compound CN(C)CC(O)CN(C)C JGVZJRHAZOBPMW-UHFFFAOYSA-N 0.000 description 1
- ZTMTUFBSNMOLBU-UHFFFAOYSA-N 1,5-dibromo-2h-pyrazin-3-amine Chemical compound NC1=NC(Br)=CN(Br)C1 ZTMTUFBSNMOLBU-UHFFFAOYSA-N 0.000 description 1
- ZLCBEFWNKWMAMF-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(5-methoxypyrazin-2-yl)urea Chemical compound C1=NC(OC)=CN=C1NC(=O)NC1=CC(C)=CC=C1OC ZLCBEFWNKWMAMF-UHFFFAOYSA-N 0.000 description 1
- CGTLTXAJQTZCIU-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 CGTLTXAJQTZCIU-UHFFFAOYSA-N 0.000 description 1
- OCSSQNUZJAWPIJ-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(5-phenylpyrazin-2-yl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C=2C=CC=CC=2)C=N1 OCSSQNUZJAWPIJ-UHFFFAOYSA-N 0.000 description 1
- PSJAZZXARPAYNL-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(6-methoxypyrazin-2-yl)urea Chemical compound COC1=CN=CC(NC(=O)NC=2C(=CC=C(C)C=2)OC)=N1 PSJAZZXARPAYNL-UHFFFAOYSA-N 0.000 description 1
- RZOCQQKIRHAPBK-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(6-phenylmethoxypyrazin-2-yl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=CC(OCC=2C=CC=CC=2)=N1 RZOCQQKIRHAPBK-UHFFFAOYSA-N 0.000 description 1
- NMIUOGOFUHFIKW-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-(6-phenylpyrazin-2-yl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=CC(C=2C=CC=CC=2)=N1 NMIUOGOFUHFIKW-UHFFFAOYSA-N 0.000 description 1
- BZXYFHHAHLMOGE-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-[5-(trifluoromethyl)pyrazin-2-yl]urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C(F)(F)F)C=N1 BZXYFHHAHLMOGE-UHFFFAOYSA-N 0.000 description 1
- ILQCDLWILNHVPG-UHFFFAOYSA-N 1-(2-methoxy-5-methylphenyl)-3-quinoxalin-2-ylurea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C=CC=C2)C2=N1 ILQCDLWILNHVPG-UHFFFAOYSA-N 0.000 description 1
- FRIQOJQCDJKFHW-UHFFFAOYSA-N 1-(2-methylsulfanylphenyl)-3-pyrazin-2-ylurea Chemical compound CSC1=CC=CC=C1NC(=O)NC1=CN=CC=N1 FRIQOJQCDJKFHW-UHFFFAOYSA-N 0.000 description 1
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 1
- HGEXZNBTICYGBI-UHFFFAOYSA-N 1-(3,5-dibromopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=NC=C(Br)N=C1Br HGEXZNBTICYGBI-UHFFFAOYSA-N 0.000 description 1
- CLAONSGOXQCSFQ-UHFFFAOYSA-N 1-(3,6-dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=NC(C)=CN=C1C CLAONSGOXQCSFQ-UHFFFAOYSA-N 0.000 description 1
- SJYKMKARBICXIH-UHFFFAOYSA-N 1-(3-bromo-5-phenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=NC=C(C=2C=CC=CC=2)N=C1Br SJYKMKARBICXIH-UHFFFAOYSA-N 0.000 description 1
- CVDGNRZPDAXOQO-UHFFFAOYSA-N 1-(3-hydroxypropyl)pyrrolidin-2-one Chemical compound OCCCN1CCCC1=O CVDGNRZPDAXOQO-UHFFFAOYSA-N 0.000 description 1
- GYURMKNHGZSMAX-UHFFFAOYSA-N 1-(5,6-dimethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C(C)=N1 GYURMKNHGZSMAX-UHFFFAOYSA-N 0.000 description 1
- URTFBWQWNMHIDH-UHFFFAOYSA-N 1-(5,6-diphenylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC(N=C1C=2C=CC=CC=2)=CN=C1C1=CC=CC=C1 URTFBWQWNMHIDH-UHFFFAOYSA-N 0.000 description 1
- OCPVWVFYPLCGGM-UHFFFAOYSA-N 1-(5-cyanopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C#N)C=N1 OCPVWVFYPLCGGM-UHFFFAOYSA-N 0.000 description 1
- BKBXHOVRGLBVBM-UHFFFAOYSA-N 1-(5-ethylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound C1=NC(CC)=CN=C1NC(=O)NC1=CC(C)=CC=C1OC BKBXHOVRGLBVBM-UHFFFAOYSA-N 0.000 description 1
- CHVRVVYXLLHJRJ-UHFFFAOYSA-N 1-(5-ethynylpyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C#C)C=N1 CHVRVVYXLLHJRJ-UHFFFAOYSA-N 0.000 description 1
- WMTSCDPQMNTISJ-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-(5-methyl-2-pyridin-2-yloxyphenyl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OC1=CC=CC=N1 WMTSCDPQMNTISJ-UHFFFAOYSA-N 0.000 description 1
- IJEUSZXITOZVTC-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-(5-methyl-2-pyridin-3-yloxyphenyl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OC1=CC=CN=C1 IJEUSZXITOZVTC-UHFFFAOYSA-N 0.000 description 1
- YGXIXTYYPGXAQC-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-(5-methyl-2-pyridin-4-yloxyphenyl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OC1=CC=NC=C1 YGXIXTYYPGXAQC-UHFFFAOYSA-N 0.000 description 1
- MNLPQUXLIQBKQO-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[2-(pyridin-3-ylmethoxy)-5-(trifluoromethyl)phenyl]urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1OCC1=CC=CN=C1 MNLPQUXLIQBKQO-UHFFFAOYSA-N 0.000 description 1
- IGYHTJUCYWXJMT-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(1-pyridin-3-ylethoxy)phenyl]urea Chemical compound C=1C=CN=CC=1C(C)OC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 IGYHTJUCYWXJMT-UHFFFAOYSA-N 0.000 description 1
- VVHTYLQLLSEEKS-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyridin-2-ylethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCC1=CC=CC=N1 VVHTYLQLLSEEKS-UHFFFAOYSA-N 0.000 description 1
- YYUGHYYQYWIEKG-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyridin-3-ylethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCC1=CC=CN=C1 YYUGHYYQYWIEKG-UHFFFAOYSA-N 0.000 description 1
- WZVAYQHJCWQTPD-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(2-pyrrolidin-1-ylethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCN1CCCC1 WZVAYQHJCWQTPD-UHFFFAOYSA-N 0.000 description 1
- PKBAXHQGUDIZEE-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(3-pyridin-2-ylpropoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCCC1=CC=CC=N1 PKBAXHQGUDIZEE-UHFFFAOYSA-N 0.000 description 1
- UGWLUEWNVOHTKJ-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(3-pyridin-3-ylpropoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCCC1=CC=CN=C1 UGWLUEWNVOHTKJ-UHFFFAOYSA-N 0.000 description 1
- FSYJZFBFCWGETB-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(3-pyridin-4-ylpropoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCCC1=CC=NC=C1 FSYJZFBFCWGETB-UHFFFAOYSA-N 0.000 description 1
- VDYRRBKCRVUPBG-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-2-ylmethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CC=CC=N1 VDYRRBKCRVUPBG-UHFFFAOYSA-N 0.000 description 1
- ZITSAWAJSPKAEE-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CC=CN=C1 ZITSAWAJSPKAEE-UHFFFAOYSA-N 0.000 description 1
- QMCXOXQZYAXZEX-UHFFFAOYSA-N 1-(5-methylpyrazin-2-yl)-3-[5-methyl-2-(pyridin-4-ylmethoxy)phenyl]urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CC=NC=C1 QMCXOXQZYAXZEX-UHFFFAOYSA-N 0.000 description 1
- CJGZPTBGJFSJDX-UHFFFAOYSA-N 1-(6-aminopyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=CC(N)=N1 CJGZPTBGJFSJDX-UHFFFAOYSA-N 0.000 description 1
- HVBWPGIJUOVGKF-UHFFFAOYSA-N 1-(6-chloropyrazin-2-yl)-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=CC(Cl)=N1 HVBWPGIJUOVGKF-UHFFFAOYSA-N 0.000 description 1
- OEWYWFJWBZNJJG-UHFFFAOYSA-N 1-(aziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CC1 OEWYWFJWBZNJJG-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- AXLBAQNITHBOAQ-UHFFFAOYSA-N 1-(difluoromethoxy)-2-isocyanatobenzene 1-[2-(difluoromethoxy)phenyl]-3-pyrazin-2-ylurea Chemical compound FC(OC1=C(C=CC=C1)N=C=O)F.FC(OC1=C(C=CC=C1)NC(=O)NC1=NC=CN=C1)F AXLBAQNITHBOAQ-UHFFFAOYSA-N 0.000 description 1
- YIALOSPTKOFOPE-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=CC=N1 YIALOSPTKOFOPE-UHFFFAOYSA-N 0.000 description 1
- MOKGROYFNDBWLZ-UHFFFAOYSA-N 1-[2-(1-benzylpiperidin-4-yl)oxy-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OC(CC1)CCN1CC1=CC=CC=C1 MOKGROYFNDBWLZ-UHFFFAOYSA-N 0.000 description 1
- IIIQLASADHXVKG-UHFFFAOYSA-N 1-[2-(1h-imidazol-5-ylmethoxy)-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CN=CN1 IIIQLASADHXVKG-UHFFFAOYSA-N 0.000 description 1
- UYXDRLSQKXOEGV-UHFFFAOYSA-N 1-[2-(4-methyl-2-nitrophenoxy)ethyl]aziridine Chemical compound [O-][N+](=O)C1=CC(C)=CC=C1OCCN1CC1 UYXDRLSQKXOEGV-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- CHROQWLBGGJMDP-UHFFFAOYSA-N 1-[2-[1,3-bis(dimethylamino)propan-2-yloxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN(C)CC(CN(C)C)OC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 CHROQWLBGGJMDP-UHFFFAOYSA-N 0.000 description 1
- PPCOSONOFULCHH-UHFFFAOYSA-N 1-[2-[2-(aziridin-1-yl)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCN1CC1 PPCOSONOFULCHH-UHFFFAOYSA-N 0.000 description 1
- BGBVHTWXVCEKMH-UHFFFAOYSA-N 1-[2-[2-(dimethylamino)ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN(C)CCOC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 BGBVHTWXVCEKMH-UHFFFAOYSA-N 0.000 description 1
- YZOCCYVFZGCTNW-UHFFFAOYSA-N 1-[2-[2-(dimethylamino)ethoxy]-5-methylphenyl]-3-pyrazin-2-ylurea Chemical compound CN(C)CCOC1=CC=C(C)C=C1NC(=O)NC1=CN=CC=N1 YZOCCYVFZGCTNW-UHFFFAOYSA-N 0.000 description 1
- IZQILSSTAKBXFS-UHFFFAOYSA-N 1-[2-[2-[4-(dimethylamino)phenyl]ethoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=CC(N(C)C)=CC=C1CCOC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 IZQILSSTAKBXFS-UHFFFAOYSA-N 0.000 description 1
- CCIQPVXQLVXSOF-UHFFFAOYSA-N 1-[2-[3-(dimethylamino)propoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN(C)CCCOC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 CCIQPVXQLVXSOF-UHFFFAOYSA-N 0.000 description 1
- DEANJCZSZFJMFE-UHFFFAOYSA-N 1-[2-[[3-(dimethylamino)phenyl]methoxy]-5-methylphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN(C)C1=CC=CC(COC=2C(=CC(C)=CC=2)NC(=O)NC=2N=CC(C)=NC=2)=C1 DEANJCZSZFJMFE-UHFFFAOYSA-N 0.000 description 1
- ADEFUSGYAUBKHJ-UHFFFAOYSA-N 1-[2-methoxy-4-(methoxymethyl)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC(COC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 ADEFUSGYAUBKHJ-UHFFFAOYSA-N 0.000 description 1
- ZQIHDDPQEJJJHR-UHFFFAOYSA-N 1-[2-methoxy-4-[(pyridin-2-ylsulfonylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNS(=O)(=O)C1=CC=CC=N1 ZQIHDDPQEJJJHR-UHFFFAOYSA-N 0.000 description 1
- XZFQHSZHGFDXMH-UHFFFAOYSA-N 1-[2-methoxy-4-[(thiophen-2-ylsulfonylamino)methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNS(=O)(=O)C1=CC=CS1 XZFQHSZHGFDXMH-UHFFFAOYSA-N 0.000 description 1
- DVCJBJGJRSIDRO-UHFFFAOYSA-N 1-[2-methoxy-4-[[(2-methoxyphenyl)methylamino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC=CC=C1CNCC(C=C1OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 DVCJBJGJRSIDRO-UHFFFAOYSA-N 0.000 description 1
- NTQOQKQLZJTYAN-UHFFFAOYSA-N 1-[2-methoxy-4-[[(3-methoxyphenyl)methylamino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC=CC(CNCC=2C=C(OC)C(NC(=O)NC=3N=CC(C)=NC=3)=CC=2)=C1 NTQOQKQLZJTYAN-UHFFFAOYSA-N 0.000 description 1
- VPIVHTYKVXOPSD-UHFFFAOYSA-N 1-[2-methoxy-4-[[(4-methoxyphenyl)methylamino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNCC(C=C1OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 VPIVHTYKVXOPSD-UHFFFAOYSA-N 0.000 description 1
- LLWKFAIEDFCXTB-UHFFFAOYSA-N 1-[2-methoxy-4-[[(4-methoxyphenyl)sulfonylamino]methyl]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCC(C=C1OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 LLWKFAIEDFCXTB-UHFFFAOYSA-N 0.000 description 1
- XJKIGNUTTZAWDJ-UHFFFAOYSA-N 1-[3,4-difluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(F)C(F)=C1OCC1=CC=CN=C1 XJKIGNUTTZAWDJ-UHFFFAOYSA-N 0.000 description 1
- UWSRAEGENAFSKJ-UHFFFAOYSA-N 1-[3-benzyl-5-(4-methoxyphenyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea Chemical compound C1=CC(OC)=CC=C1C(N=C1CC=2C=CC=CC=2)=CN=C1NC(=O)NC1=CC(C)=CC=C1OC UWSRAEGENAFSKJ-UHFFFAOYSA-N 0.000 description 1
- NLYPOSJKRNFKIY-UHFFFAOYSA-N 1-[4-(benzenesulfonamidomethyl)-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNS(=O)(=O)C1=CC=CC=C1 NLYPOSJKRNFKIY-UHFFFAOYSA-N 0.000 description 1
- IIAFTXCZLGGPDG-UHFFFAOYSA-N 1-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound COC1=CC(CN(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 IIAFTXCZLGGPDG-UHFFFAOYSA-N 0.000 description 1
- JZQHWOWXYWQWPI-UHFFFAOYSA-N 1-[4-fluoro-2-(1-methylpiperidin-4-yl)oxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1CN(C)CCC1OC1=CC(F)=CC=C1NC(=O)NC1=CN=C(C)C=N1 JZQHWOWXYWQWPI-UHFFFAOYSA-N 0.000 description 1
- UTNHGTNYOMGKLO-UHFFFAOYSA-N 1-[4-fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(F)C=C1OCC1=CC=CN=C1 UTNHGTNYOMGKLO-UHFFFAOYSA-N 0.000 description 1
- KGZMFKGWLZFSSD-UHFFFAOYSA-N 1-[5-(aminomethyl)pyrazin-2-yl]-3-(2-methoxy-5-methylphenyl)urea Chemical compound COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(CN)C=N1 KGZMFKGWLZFSSD-UHFFFAOYSA-N 0.000 description 1
- MHZJGPVDSMKXEQ-UHFFFAOYSA-N 1-[5-(methanesulfonamido)-2-methoxyphenyl]-3-pyrazin-2-ylurea Chemical compound COC1=CC=C(NS(C)(=O)=O)C=C1NC(=O)NC1=CN=CC=N1 MHZJGPVDSMKXEQ-UHFFFAOYSA-N 0.000 description 1
- WQKUTGMYNOZZCR-UHFFFAOYSA-N 1-[5-fluoro-2-(1-methylpiperidin-4-yl)oxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1CN(C)CCC1OC1=CC=C(F)C=C1NC(=O)NC1=CN=C(C)C=N1 WQKUTGMYNOZZCR-UHFFFAOYSA-N 0.000 description 1
- IFACCBLVURYBOQ-UHFFFAOYSA-N 1-[5-fluoro-2-(pyridin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC(F)=CC=C1OCC1=CC=CN=C1 IFACCBLVURYBOQ-UHFFFAOYSA-N 0.000 description 1
- ATJWVMNWMCNFLM-UHFFFAOYSA-N 1-[5-methyl-2-(1-methylpiperidin-3-yl)oxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1N(C)CCCC1OC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 ATJWVMNWMCNFLM-UHFFFAOYSA-N 0.000 description 1
- OQQNNRRZMRAYQC-UHFFFAOYSA-N 1-[5-methyl-2-(1-methylpiperidin-4-yl)oxyphenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1CN(C)CCC1OC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 OQQNNRRZMRAYQC-UHFFFAOYSA-N 0.000 description 1
- MSQLBKBQXYPCPV-UHFFFAOYSA-N 1-[5-methyl-2-(2-morpholin-4-ylethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCN1CCOCC1 MSQLBKBQXYPCPV-UHFFFAOYSA-N 0.000 description 1
- SOFUVOWVKANYHO-UHFFFAOYSA-N 1-[5-methyl-2-(2-morpholin-4-ylethoxy)phenyl]-3-pyrazin-2-ylurea Chemical compound C=1N=CC=NC=1NC(=O)NC1=CC(C)=CC=C1OCCN1CCOCC1 SOFUVOWVKANYHO-UHFFFAOYSA-N 0.000 description 1
- PFQGZSNKSTWXJR-UHFFFAOYSA-N 1-[5-methyl-2-(3-piperidin-1-ylpropoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCCCN1CCCCC1 PFQGZSNKSTWXJR-UHFFFAOYSA-N 0.000 description 1
- KPUPWDSDRFBQMS-UHFFFAOYSA-N 1-[5-methyl-2-(piperidin-3-ylmethoxy)phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1CCCNC1 KPUPWDSDRFBQMS-UHFFFAOYSA-N 0.000 description 1
- DVJGVWAAIDUWHT-UHFFFAOYSA-N 1-[5-methyl-2-(pyridin-3-ylmethoxy)phenyl]-3-pyrazin-2-ylurea Chemical compound C=1N=CC=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1=CC=CN=C1 DVJGVWAAIDUWHT-UHFFFAOYSA-N 0.000 description 1
- ODSSIIRMBFRNKX-UHFFFAOYSA-N 1-[5-methyl-2-[(1-methylpiperidin-2-yl)methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN1CCCCC1COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 ODSSIIRMBFRNKX-UHFFFAOYSA-N 0.000 description 1
- NIIOEOQBLIBYSQ-UHFFFAOYSA-N 1-[5-methyl-2-[(1-methylpiperidin-3-yl)methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1N(C)CCCC1COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 NIIOEOQBLIBYSQ-UHFFFAOYSA-N 0.000 description 1
- MAPNFSSDJQCPEU-UHFFFAOYSA-N 1-[5-methyl-2-[(1-methylpyrrolidin-3-yl)methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound C1N(C)CCC1COC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 MAPNFSSDJQCPEU-UHFFFAOYSA-N 0.000 description 1
- IBOBSNALDTWHEQ-UHFFFAOYSA-N 1-[5-methyl-2-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea Chemical compound CN1CCCC1CCOC1=CC=C(C)C=C1NC(=O)NC1=CN=C(C)C=N1 IBOBSNALDTWHEQ-UHFFFAOYSA-N 0.000 description 1
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- BPPZXJZYCOETDA-UHFFFAOYSA-N 1-benzylpiperidin-4-ol Chemical compound C1CC(O)CCN1CC1=CC=CC=C1 BPPZXJZYCOETDA-UHFFFAOYSA-N 0.000 description 1
- NBBRIIZFMWSCHJ-UHFFFAOYSA-N 1-benzylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1C(N)CCN1CC1=CC=CC=C1 NBBRIIZFMWSCHJ-UHFFFAOYSA-N 0.000 description 1
- CLAWVAYUCKGORV-UHFFFAOYSA-N 1-bromo-2h-pyrazin-3-amine Chemical compound NC1=NC=CN(Br)C1 CLAWVAYUCKGORV-UHFFFAOYSA-N 0.000 description 1
- QVPCVWIETKOKGS-UHFFFAOYSA-N 1-methyl-2h-pyrazin-3-amine Chemical compound CN1CC(N)=NC=C1 QVPCVWIETKOKGS-UHFFFAOYSA-N 0.000 description 1
- HCKNAJXCHMACDN-UHFFFAOYSA-N 1-methylpiperidine-4-carboxylic acid Chemical compound CN1CCC(C(O)=O)CC1 HCKNAJXCHMACDN-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YDWXOKSCKDJRQZ-UHFFFAOYSA-N 1-phenyl-4-(trifluoromethyl)pyrazole-3-carbonyl chloride Chemical compound N1=C(C(Cl)=O)C(C(F)(F)F)=CN1C1=CC=CC=C1 YDWXOKSCKDJRQZ-UHFFFAOYSA-N 0.000 description 1
- MYFPIRLHESHOGR-UHFFFAOYSA-N 1-propan-2-ylpyrrolidin-3-ol Chemical compound CC(C)N1CCC(O)C1 MYFPIRLHESHOGR-UHFFFAOYSA-N 0.000 description 1
- QMDUEBURHKSKDG-UHFFFAOYSA-N 1-pyridin-3-ylethanol Chemical compound CC(O)C1=CC=CN=C1 QMDUEBURHKSKDG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- KEGOHDCHURMFKX-UHFFFAOYSA-N 2,3-difluoro-6-nitrophenol Chemical compound OC1=C(F)C(F)=CC=C1[N+]([O-])=O KEGOHDCHURMFKX-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- VYONOYYDEFODAJ-UHFFFAOYSA-N 2-(1-Aziridinyl)ethanol Chemical compound OCCN1CC1 VYONOYYDEFODAJ-UHFFFAOYSA-N 0.000 description 1
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 1
- FYVMBPXFPFAECB-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanol Chemical compound CN1CCCC1CCO FYVMBPXFPFAECB-UHFFFAOYSA-N 0.000 description 1
- HWRVPXNETSIQBU-UHFFFAOYSA-N 2-(2-amino-4-methylphenoxy)-n,n,n',n'-tetramethylpropane-1,3-diamine Chemical compound CN(C)CC(CN(C)C)OC1=CC=C(C)C=C1N HWRVPXNETSIQBU-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- KAQQZILVGMWVDH-UHFFFAOYSA-N 2-(dimethylamino)-n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]acetamide Chemical compound COC1=CC(CNC(=O)CN(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 KAQQZILVGMWVDH-UHFFFAOYSA-N 0.000 description 1
- VTYRPALGSNDUQQ-UHFFFAOYSA-N 2-(dimethylamino)acetyl chloride Chemical compound CN(C)CC(Cl)=O VTYRPALGSNDUQQ-UHFFFAOYSA-N 0.000 description 1
- JLTBWYIUMFEOTN-UHFFFAOYSA-N 2-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=CC=C1S(Cl)(=O)=O JLTBWYIUMFEOTN-UHFFFAOYSA-N 0.000 description 1
- UKFTXWKNVSVVCJ-UHFFFAOYSA-N 2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol;hydron;dichloride Chemical class Cl.Cl.NNC1=CC=C(N(CCO)CCO)N=N1 UKFTXWKNVSVVCJ-UHFFFAOYSA-N 0.000 description 1
- JCQNJRIAWDVIID-UHFFFAOYSA-N 2-[2-(aziridin-1-yl)ethoxy]-5-methylaniline Chemical compound NC1=CC(C)=CC=C1OCCN1CC1 JCQNJRIAWDVIID-UHFFFAOYSA-N 0.000 description 1
- ZEOSWLLDQWTNEE-UHFFFAOYSA-N 2-[2-[4-(dimethylamino)phenyl]ethoxy]-5-methylaniline Chemical compound C1=CC(N(C)C)=CC=C1CCOC1=CC=C(C)C=C1N ZEOSWLLDQWTNEE-UHFFFAOYSA-N 0.000 description 1
- UVCFVRGIQMNOLQ-UHFFFAOYSA-N 2-[2-[benzyl(methyl)amino]ethoxy]-5-methylaniline Chemical compound C=1C=CC=CC=1CN(C)CCOC1=CC=C(C)C=C1N UVCFVRGIQMNOLQ-UHFFFAOYSA-N 0.000 description 1
- CDTPAAZQBPSVGS-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]ethanol Chemical compound CN(C)C1=CC=C(CCO)C=C1 CDTPAAZQBPSVGS-UHFFFAOYSA-N 0.000 description 1
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 description 1
- BKLYFKFMXIFTCT-UHFFFAOYSA-N 2-[cyclohexyl(methyl)amino]-n-[3-methoxy-4-(pyrazin-2-ylcarbamoylamino)phenyl]propanamide Chemical compound C=1C=C(NC(=O)NC=2N=CC=NC=2)C(OC)=CC=1NC(=O)C(C)N(C)C1CCCCC1 BKLYFKFMXIFTCT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BHTKIYIEMXRHGL-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)phenol Chemical compound NC1=CC(C(F)(F)F)=CC=C1O BHTKIYIEMXRHGL-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- IFUYDRODXORJSO-UHFFFAOYSA-N 2-azidopyrazine Chemical compound [N-]=[N+]=NC1=CN=CC=N1 IFUYDRODXORJSO-UHFFFAOYSA-N 0.000 description 1
- TVLMWBZLDKVQPC-UHFFFAOYSA-N 2-benzyl-1-(4-methoxyphenyl)-2h-pyrazin-3-amine Chemical compound C1=CC(OC)=CC=C1N1C(CC=2C=CC=CC=2)C(N)=NC=C1 TVLMWBZLDKVQPC-UHFFFAOYSA-N 0.000 description 1
- XPBJPGMCFKYBBV-UHFFFAOYSA-N 2-bromoethyl-[2-hydroxy-3-(2-nitroimidazol-1-yl)propyl]azanium;bromide Chemical compound Br.BrCCNCC(O)CN1C=CN=C1[N+]([O-])=O XPBJPGMCFKYBBV-UHFFFAOYSA-N 0.000 description 1
- BTGGHNHGPURMEO-UHFFFAOYSA-N 2-chloro-3,5-dimethylpyrazine Chemical compound CC1=CN=C(Cl)C(C)=N1 BTGGHNHGPURMEO-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- BYHVGQHIAFURIL-UHFFFAOYSA-N 2-chloroquinoxaline Chemical compound C1=CC=CC2=NC(Cl)=CN=C21 BYHVGQHIAFURIL-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- LEJIZOMNHVTYMC-UHFFFAOYSA-N 2-isocyanato-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C=C1N=C=O LEJIZOMNHVTYMC-UHFFFAOYSA-N 0.000 description 1
- AOBWECDVSWTMSU-UHFFFAOYSA-N 2-methoxy-1-nitro-4-(phenylmethoxymethyl)benzene Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(COCC=2C=CC=CC=2)=C1 AOBWECDVSWTMSU-UHFFFAOYSA-N 0.000 description 1
- SUXMMGMGFQBFFN-UHFFFAOYSA-N 2-methoxy-4-[2-[2-(3-methoxy-4-nitrophenyl)-1-phenylethoxy]-2-phenylethyl]-1-nitrobenzene Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CC(OC(CC=2C=C(OC)C(=CC=2)[N+]([O-])=O)C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SUXMMGMGFQBFFN-UHFFFAOYSA-N 0.000 description 1
- VOTZJLLPYYCZRY-UHFFFAOYSA-N 2-methoxy-4-nitrophenyl isocyanate Chemical compound COC1=CC([N+]([O-])=O)=CC=C1N=C=O VOTZJLLPYYCZRY-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- SYDNSSSQVSOXTN-UHFFFAOYSA-N 2-nitro-p-cresol Chemical compound CC1=CC=C(O)C([N+]([O-])=O)=C1 SYDNSSSQVSOXTN-UHFFFAOYSA-N 0.000 description 1
- JMZMVURYVHXGKK-UHFFFAOYSA-N 2-pyridin-2-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=N1 JMZMVURYVHXGKK-UHFFFAOYSA-N 0.000 description 1
- BXGYBSJAZFGIPX-UHFFFAOYSA-N 2-pyridin-2-ylethanol Chemical compound OCCC1=CC=CC=N1 BXGYBSJAZFGIPX-UHFFFAOYSA-N 0.000 description 1
- YPWSASPSYAWQRK-UHFFFAOYSA-N 2-pyridin-3-ylethanol Chemical compound OCCC1=CC=CN=C1 YPWSASPSYAWQRK-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- JIUOASFIFVEUIE-UHFFFAOYSA-N 3,4-difluoro-2-(pyridin-3-ylmethoxy)aniline Chemical compound NC1=CC=C(F)C(F)=C1OCC1=CC=CN=C1 JIUOASFIFVEUIE-UHFFFAOYSA-N 0.000 description 1
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 1
- YWACNLNUNCLRJR-UHFFFAOYSA-N 3-(2-methoxy-5-methylphenyl)-1-methyl-1-pyrazin-2-ylurea Chemical compound COC1=CC=C(C)C=C1NC(=O)N(C)C1=CN=CC=N1 YWACNLNUNCLRJR-UHFFFAOYSA-N 0.000 description 1
- NUGLIYXAARVRPQ-UHFFFAOYSA-N 3-(2-nitroimidazol-1-yl)propane-1,2-diol Chemical compound OCC(O)CN1C=CN=C1[N+]([O-])=O NUGLIYXAARVRPQ-UHFFFAOYSA-N 0.000 description 1
- SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 description 1
- OZAHKEBTSYHZKU-UHFFFAOYSA-N 3-(dimethylamino)-n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]benzamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C1=CC=CC(N(C)C)=C1 OZAHKEBTSYHZKU-UHFFFAOYSA-N 0.000 description 1
- JSNWINNGICSYQK-UHFFFAOYSA-N 3-[(2,3-difluoro-6-nitrophenoxy)methyl]pyridine Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1OCC1=CC=CN=C1 JSNWINNGICSYQK-UHFFFAOYSA-N 0.000 description 1
- RLHIGORQJFLNFF-UHFFFAOYSA-N 3-[(4-fluoro-2-nitrophenoxy)methyl]pyridine Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1OCC1=CC=CN=C1 RLHIGORQJFLNFF-UHFFFAOYSA-N 0.000 description 1
- YFMCMONFKTZWBN-UHFFFAOYSA-N 3-[(5-fluoro-2-nitrophenoxy)methyl]pyridine Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1OCC1=CC=CN=C1 YFMCMONFKTZWBN-UHFFFAOYSA-N 0.000 description 1
- XZWOUVUJJFMCHW-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-(2-morpholin-4-ylethyl)benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)NCCN2CCOCC2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 XZWOUVUJJFMCHW-UHFFFAOYSA-N 0.000 description 1
- GAEJEOFNOJQIHN-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)NCCC2N(CCC2)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 GAEJEOFNOJQIHN-UHFFFAOYSA-N 0.000 description 1
- HCAJTLKDNBOEDK-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound CN(C)CCCOC1=CC(C(N)=O)=CC=C1NC(=O)NC1=CN=C(C)C=N1 HCAJTLKDNBOEDK-UHFFFAOYSA-N 0.000 description 1
- XZLKKYPDNQHEFM-UHFFFAOYSA-N 3-[3-(dimethylamino)propoxy]-n,n-dimethyl-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)N(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 XZLKKYPDNQHEFM-UHFFFAOYSA-N 0.000 description 1
- TZZDVPMABRWKIZ-MFTLXVFQSA-N 3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-MFTLXVFQSA-N 0.000 description 1
- NVBHFTUCKKMAKQ-UHFFFAOYSA-N 3-[[4-methyl-2-[(5-methylpyrazin-2-yl)carbamoylamino]phenoxy]methyl]-3,4-dihydro-2H-quinoline-1-carboxylic acid Chemical compound C=1C(C)=CC=C(OCC2CC3=CC=CC=C3N(C(O)=O)C2)C=1NC(=O)NC1=CN=C(C)C=N1 NVBHFTUCKKMAKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- SQTVGFPZRMSHBC-UHFFFAOYSA-N 3-methoxy-4-(pyrazin-2-ylcarbamoylamino)-n-(2-pyridin-2-ylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCC=2N=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 SQTVGFPZRMSHBC-UHFFFAOYSA-N 0.000 description 1
- JAYNMMVMXQPYHO-UHFFFAOYSA-N 3-methoxy-4-(pyrazin-2-ylcarbamoylamino)-n-(2-pyridin-4-ylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCC=2C=CN=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 JAYNMMVMXQPYHO-UHFFFAOYSA-N 0.000 description 1
- DCAMINGPBBPZRF-UHFFFAOYSA-N 3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-(2-pyridin-2-ylethyl)benzamide Chemical compound COC1=CC(C(=O)NCCC=2N=CC=CC=2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 DCAMINGPBBPZRF-UHFFFAOYSA-N 0.000 description 1
- OPPSRFAEEGKKNJ-UHFFFAOYSA-N 3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-(3-morpholin-4-ylpropyl)benzamide Chemical compound COC1=CC(C(=O)NCCCN2CCOCC2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 OPPSRFAEEGKKNJ-UHFFFAOYSA-N 0.000 description 1
- PWURRRRGLCVBMX-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1[N+]([O-])=O PWURRRRGLCVBMX-UHFFFAOYSA-N 0.000 description 1
- IKLKWZAUNXRTJH-UHFFFAOYSA-N 3-methoxy-n-(2-phenylethyl)-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCC=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 IKLKWZAUNXRTJH-UHFFFAOYSA-N 0.000 description 1
- IPUUSLJJMAPUCN-UHFFFAOYSA-N 3-methoxy-n-(3-morpholin-4-ylpropyl)-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCN2CCOCC2)=CC=C1NC(=O)NC1=CN=CC=N1 IPUUSLJJMAPUCN-UHFFFAOYSA-N 0.000 description 1
- UDFWOPQDNZTIPS-UHFFFAOYSA-N 3-methoxy-n-(3-phenylpropyl)-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCC=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 UDFWOPQDNZTIPS-UHFFFAOYSA-N 0.000 description 1
- RFBGHXDIDBASMF-UHFFFAOYSA-N 3-methoxy-n-[3-(methylamino)propyl]-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCNC)=CC=C1NC(=O)NC1=CN=CC=N1 RFBGHXDIDBASMF-UHFFFAOYSA-N 0.000 description 1
- IHAMHYRLXHWLMR-UHFFFAOYSA-N 3-methoxy-n-[3-(n-methylanilino)propyl]-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 IHAMHYRLXHWLMR-UHFFFAOYSA-N 0.000 description 1
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 1
- VZKSLWJLGAGPIU-UHFFFAOYSA-N 3-morpholin-4-ylpropan-1-ol Chemical compound OCCCN1CCOCC1 VZKSLWJLGAGPIU-UHFFFAOYSA-N 0.000 description 1
- PLRXAFVBCHEMGD-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-ol Chemical compound OCCCN1CCCCC1 PLRXAFVBCHEMGD-UHFFFAOYSA-N 0.000 description 1
- FVZXYJDGVYLMDB-UHFFFAOYSA-N 3-pyridin-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CC=N1 FVZXYJDGVYLMDB-UHFFFAOYSA-N 0.000 description 1
- ZUGAIMFLQLPTKB-UHFFFAOYSA-N 3-pyridin-3-ylpropan-1-ol Chemical compound OCCCC1=CC=CN=C1 ZUGAIMFLQLPTKB-UHFFFAOYSA-N 0.000 description 1
- PZVZGDBCMQBRMA-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-ol Chemical compound OCCCC1=CC=NC=C1 PZVZGDBCMQBRMA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- FVCYTBPYWUUOKP-UHFFFAOYSA-N 4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(C(N)=O)C=C1OCC1=CC=CN=C1 FVCYTBPYWUUOKP-UHFFFAOYSA-N 0.000 description 1
- DYWORBCUWNJLRX-UHFFFAOYSA-N 4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-(2-morpholin-4-ylethyl)-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(C(=O)NCCN2CCOCC2)C=C1OCC1=CC=CN=C1 DYWORBCUWNJLRX-UHFFFAOYSA-N 0.000 description 1
- ZRSCJUADOFHYEG-UHFFFAOYSA-N 4-[4-methoxy-3-(pyrazin-2-ylcarbamoylamino)anilino]-4-oxobutanoic acid Chemical compound COC1=CC=C(NC(=O)CCC(O)=O)C=C1NC(=O)NC1=CN=CC=N1 ZRSCJUADOFHYEG-UHFFFAOYSA-N 0.000 description 1
- DLGZLIXYVSQGOX-UHFFFAOYSA-N 4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=COC(C(N)=O)=C1 DLGZLIXYVSQGOX-UHFFFAOYSA-N 0.000 description 1
- GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 description 1
- IXJFWBNYFTWBOR-UHFFFAOYSA-N 4-amino-3-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1OC(F)(F)F IXJFWBNYFTWBOR-UHFFFAOYSA-N 0.000 description 1
- KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
- GVCLNACSYKYUHP-UHFFFAOYSA-N 4-amino-7-(2-hydroxyethoxymethyl)pyrrolo[2,3-d]pyrimidine-5-carbothioamide Chemical compound C1=NC(N)=C2C(C(=S)N)=CN(COCCO)C2=N1 GVCLNACSYKYUHP-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BPNHKEIFLGMJCE-UHFFFAOYSA-N 4-fluoro-2-(pyridin-3-ylmethoxy)aniline Chemical compound NC1=CC=C(F)C=C1OCC1=CC=CN=C1 BPNHKEIFLGMJCE-UHFFFAOYSA-N 0.000 description 1
- NZOXETSSTBMIEU-UHFFFAOYSA-N 4-methoxy-3-(pyrazin-2-ylcarbamoylamino)-n-(2-pyridin-2-ylethyl)benzamide Chemical compound COC1=CC=C(C(=O)NCCC=2N=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 NZOXETSSTBMIEU-UHFFFAOYSA-N 0.000 description 1
- KZUDAZDJLZFJKN-UHFFFAOYSA-N 4-methoxy-3-(pyrazin-2-ylcarbamoylamino)-n-(2-pyridin-4-ylethyl)benzamide Chemical compound COC1=CC=C(C(=O)NCCC=2C=CN=CC=2)C=C1NC(=O)NC1=CN=CC=N1 KZUDAZDJLZFJKN-UHFFFAOYSA-N 0.000 description 1
- GVNPFAMXFKTBRX-UHFFFAOYSA-N 4-methoxy-n-(2-phenylethyl)-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCC=2C=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 GVNPFAMXFKTBRX-UHFFFAOYSA-N 0.000 description 1
- RKQBALLQMPZOHM-UHFFFAOYSA-N 4-methoxy-n-(3-morpholin-4-ylpropyl)-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCCN2CCOCC2)C=C1NC(=O)NC1=CN=CC=N1 RKQBALLQMPZOHM-UHFFFAOYSA-N 0.000 description 1
- TYZJLRSWRWVNQD-UHFFFAOYSA-N 4-methoxy-n-(3-phenylpropyl)-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCCC=2C=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 TYZJLRSWRWVNQD-UHFFFAOYSA-N 0.000 description 1
- PQUSMUBMBHTZPS-UHFFFAOYSA-N 4-methoxy-n-[3-(4-methylpiperazin-1-yl)propyl]-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCCN2CCN(C)CC2)C=C1NC(=O)NC1=CN=CC=N1 PQUSMUBMBHTZPS-UHFFFAOYSA-N 0.000 description 1
- SVINYVWTRNLMSL-UHFFFAOYSA-N 4-methoxy-n-[3-(n-methylanilino)propyl]-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCCN(C)C=2C=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 SVINYVWTRNLMSL-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- ILDRNIDSVAZBMZ-UHFFFAOYSA-N 5-(trifluoromethyl)pyrazin-2-amine Chemical compound NC1=CN=C(C(F)(F)F)C=N1 ILDRNIDSVAZBMZ-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- PHMZLDTZAHNAPC-UHFFFAOYSA-N 5-ethynylpyrazin-2-amine Chemical compound NC1=CN=C(C#C)C=N1 PHMZLDTZAHNAPC-UHFFFAOYSA-N 0.000 description 1
- UVEKTZLAYSXLMW-UHFFFAOYSA-N 5-fluoro-2-(pyridin-3-ylmethoxy)aniline Chemical compound NC1=CC(F)=CC=C1OCC1=CC=CN=C1 UVEKTZLAYSXLMW-UHFFFAOYSA-N 0.000 description 1
- BRFNBGWEOKQIND-UHFFFAOYSA-N 5-fluoro-2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1C(F)(F)F BRFNBGWEOKQIND-UHFFFAOYSA-N 0.000 description 1
- GSVOGLDREQTCFV-UHFFFAOYSA-N 5-fluoro-3-nitro-2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC([N+]([O-])=O)=C1C(F)(F)F GSVOGLDREQTCFV-UHFFFAOYSA-N 0.000 description 1
- NIJGCNDZTDZZTL-UHFFFAOYSA-N 5-fluoro-4-nitro-2-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(F)=C([N+]([O-])=O)C=C1C(F)(F)F NIJGCNDZTDZZTL-UHFFFAOYSA-N 0.000 description 1
- PQZQEXKKRONWAI-UHFFFAOYSA-N 5-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]-n-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1C(=O)NCCC1=CC=CC=N1 PQZQEXKKRONWAI-UHFFFAOYSA-N 0.000 description 1
- JDMBWFWJVJHJFO-UHFFFAOYSA-N 5-methyl-2-(1-methylpiperidin-3-yl)oxyaniline Chemical compound C1N(C)CCCC1OC1=CC=C(C)C=C1N JDMBWFWJVJHJFO-UHFFFAOYSA-N 0.000 description 1
- CASBOZIYUGIAQR-UHFFFAOYSA-N 5-methyl-2-(1-pyridin-3-ylethoxy)aniline Chemical compound C=1C=CN=CC=1C(C)OC1=CC=C(C)C=C1N CASBOZIYUGIAQR-UHFFFAOYSA-N 0.000 description 1
- OODLEXPOVUKVAY-UHFFFAOYSA-N 5-methyl-2-(2-pyridin-2-ylethoxy)aniline Chemical compound NC1=CC(C)=CC=C1OCCC1=CC=CC=N1 OODLEXPOVUKVAY-UHFFFAOYSA-N 0.000 description 1
- GFWNXQCQSHEIQV-UHFFFAOYSA-N 5-methyl-2-(3-pyridin-3-ylpropoxy)aniline Chemical compound NC1=CC(C)=CC=C1OCCCC1=CC=CN=C1 GFWNXQCQSHEIQV-UHFFFAOYSA-N 0.000 description 1
- OAHGPUWZFLWSIK-UHFFFAOYSA-N 5-methyl-2-(oxolan-2-ylmethoxy)aniline Chemical compound NC1=CC(C)=CC=C1OCC1OCCC1 OAHGPUWZFLWSIK-UHFFFAOYSA-N 0.000 description 1
- GWRWXWBSSHYCGQ-UHFFFAOYSA-N 5-methyl-2-(pyridin-3-ylmethoxy)aniline Chemical compound NC1=CC(C)=CC=C1OCC1=CC=CN=C1 GWRWXWBSSHYCGQ-UHFFFAOYSA-N 0.000 description 1
- ITVDABPDTUANID-UHFFFAOYSA-N 5-methyl-2-[(1-methylpiperidin-4-yl)methoxy]aniline Chemical compound C1CN(C)CCC1COC1=CC=C(C)C=C1N ITVDABPDTUANID-UHFFFAOYSA-N 0.000 description 1
- NHIKSEOMCLVZAS-UHFFFAOYSA-N 5-methyl-2-[(6-methylpyridin-3-yl)methoxy]aniline Chemical compound NC1=CC(C)=CC=C1OCC1=CC=C(C)N=C1 NHIKSEOMCLVZAS-UHFFFAOYSA-N 0.000 description 1
- XIUAFNYUTGHTST-LBPRGKRZSA-N 5-methyl-2-[[(3s)-1-methylpiperidin-3-yl]methoxy]aniline Chemical compound C1N(C)CCC[C@@H]1COC1=CC=C(C)C=C1N XIUAFNYUTGHTST-LBPRGKRZSA-N 0.000 description 1
- ODQDTYHDADPRIN-UHFFFAOYSA-N 5-methyl-2-pyridin-2-yloxyaniline Chemical compound NC1=CC(C)=CC=C1OC1=CC=CC=N1 ODQDTYHDADPRIN-UHFFFAOYSA-N 0.000 description 1
- MTLURUSPEHHIKT-UHFFFAOYSA-N 5-methyl-2-pyridin-3-yloxyaniline Chemical compound NC1=CC(C)=CC=C1OC1=CC=CN=C1 MTLURUSPEHHIKT-UHFFFAOYSA-N 0.000 description 1
- SONFTWTZVWFVGA-UHFFFAOYSA-N 5-methyl-2-pyridin-4-yloxyaniline Chemical compound NC1=CC(C)=CC=C1OC1=CC=NC=C1 SONFTWTZVWFVGA-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- RZOKQIPOABEQAM-UHFFFAOYSA-N 6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=N1 RZOKQIPOABEQAM-UHFFFAOYSA-N 0.000 description 1
- PSEVKGFJGGKCIX-UHFFFAOYSA-N 6-phenylpyrazin-2-amine Chemical compound NC1=CN=CC(C=2C=CC=CC=2)=N1 PSEVKGFJGGKCIX-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108010070075 Bacteriochlorophyll A Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000008178 Cyclin B1 Human genes 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 101100502742 Danio rerio fgf8a gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101150092822 FGF5 gene Proteins 0.000 description 1
- 101150095289 FGF7 gene Proteins 0.000 description 1
- 101150112093 FGF9 gene Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026871 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000033828 Isochromosomes Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100446521 Mus musculus Fgf6 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010064527 OSM-LIF Receptors Proteins 0.000 description 1
- 102000015278 OSM-LIF Receptors Human genes 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101500026849 Rattus norvegicus C3a anaphylatoxin Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- ZSLFCBHEINFXRS-LPEHRKFASA-N Ser-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N ZSLFCBHEINFXRS-LPEHRKFASA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 1
- ULLZEFGJRZHIJR-FQEVSTJZSA-N [(3s)-1-benzylpyrrolidin-3-yl] 3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzoate Chemical compound COC1=CC(C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 ULLZEFGJRZHIJR-FQEVSTJZSA-N 0.000 description 1
- UGXQXVDTGJCQHR-ZETCQYMHSA-N [(3s)-1-methylpiperidin-3-yl]methanol Chemical compound CN1CCC[C@H](CO)C1 UGXQXVDTGJCQHR-ZETCQYMHSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YTUXZVSDDHCTBZ-UHFFFAOYSA-N [3-(dimethylamino)phenyl]methanol Chemical compound CN(C)C1=CC=CC(CO)=C1 YTUXZVSDDHCTBZ-UHFFFAOYSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000005275 alkylenearyl group Chemical group 0.000 description 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- ZSERVQBSOBTXFV-DHHJBRQQSA-M bacteriochlorophyll a Chemical compound C1([C@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@@H](CC)[C@@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ZSERVQBSOBTXFV-DHHJBRQQSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- SFINUUKWYTWJFA-UHFFFAOYSA-N benzyl 3-[[4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]methyl]-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1=CC(C)=CC=C1OCC1CC2=CC=CC=C2N(C(=O)OCC=2C=CC=CC=2)C1 SFINUUKWYTWJFA-UHFFFAOYSA-N 0.000 description 1
- AKWDPYZLLLKFPB-UHFFFAOYSA-N benzyl 3-[[4-methyl-2-[(5-methylpyrazin-2-yl)carbamoylamino]phenoxy]methyl]-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC(CC1=CC=CC=C11)CN1C(=O)OCC1=CC=CC=C1 AKWDPYZLLLKFPB-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108010052344 histone H1 kinase Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- QDYTUZCWBJRHKK-UHFFFAOYSA-N imidazole-4-methanol Chemical compound OCC1=CNC=N1 QDYTUZCWBJRHKK-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 210000000661 isochromosome Anatomy 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- XZAAKIMHGHTXDH-UHFFFAOYSA-M lithium;hydrogen peroxide;hydroxide Chemical compound [Li+].[OH-].OO XZAAKIMHGHTXDH-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- XWNJREOZPFEKNQ-UHFFFAOYSA-N methyl 1-ethyl-3,4-dihydro-2h-quinoline-3-carboxylate Chemical compound C1=CC=C2N(CC)CC(C(=O)OC)CC2=C1 XWNJREOZPFEKNQ-UHFFFAOYSA-N 0.000 description 1
- SXZRFOHVWPDPNQ-UHFFFAOYSA-N methyl 3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzoate Chemical compound CN(C)CCCOC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 SXZRFOHVWPDPNQ-UHFFFAOYSA-N 0.000 description 1
- SYJVDGDZVJWYGT-UHFFFAOYSA-N methyl 3-methoxy-4-[(4-nitrophenoxy)carbonylamino]benzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 SYJVDGDZVJWYGT-UHFFFAOYSA-N 0.000 description 1
- DCLOQAIPDKHRSD-UHFFFAOYSA-N methyl 4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzoate Chemical compound C=1C=CN=CC=1COC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 DCLOQAIPDKHRSD-UHFFFAOYSA-N 0.000 description 1
- OPXCMVSBQCAHBZ-UHFFFAOYSA-N methyl 4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(trifluoromethoxy)benzoate Chemical compound FC(F)(F)OC1=CC(C(=O)OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 OPXCMVSBQCAHBZ-UHFFFAOYSA-N 0.000 description 1
- VOZICRAZVBGCNM-UHFFFAOYSA-N methyl 4-amino-3-(trifluoromethoxy)benzoate Chemical compound COC(=O)C1=CC=C(N)C(OC(F)(F)F)=C1 VOZICRAZVBGCNM-UHFFFAOYSA-N 0.000 description 1
- DMTTVKAFLCGQRO-UHFFFAOYSA-N methyl 4-methoxy-3-[(4-nitrobenzoyl)amino]benzoate Chemical compound COC(=O)C1=CC=C(OC)C(NC(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 DMTTVKAFLCGQRO-UHFFFAOYSA-N 0.000 description 1
- BTSSELYCHZMTEG-UHFFFAOYSA-N methyl 4-methoxy-4-(pyrazin-2-ylcarbamoylamino)cyclohexa-1,5-diene-1-carboxylate Chemical compound C1=CC(C(=O)OC)=CCC1(OC)NC(=O)NC1=CN=CC=N1 BTSSELYCHZMTEG-UHFFFAOYSA-N 0.000 description 1
- IFIIIEXJVYZXIC-UHFFFAOYSA-N methyl 5-fluoro-3-nitro-2-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(F)=CC([N+]([O-])=O)=C1C(F)(F)F IFIIIEXJVYZXIC-UHFFFAOYSA-N 0.000 description 1
- JGDCNDARQQSFBF-UHFFFAOYSA-N methyl 5-fluoro-4-nitro-2-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(F)=C([N+]([O-])=O)C=C1C(F)(F)F JGDCNDARQQSFBF-UHFFFAOYSA-N 0.000 description 1
- CLKRAHMILAWPJT-UHFFFAOYSA-N methyl 5-methoxy-3-nitro-2-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(OC)=CC([N+]([O-])=O)=C1C(F)(F)F CLKRAHMILAWPJT-UHFFFAOYSA-N 0.000 description 1
- JSFKVAICWNSZMR-UHFFFAOYSA-N methyl 5-methoxy-4-[(4-nitrophenoxy)carbonylamino]-2-(trifluoromethyl)benzoate Chemical compound C1=C(C(F)(F)F)C(C(=O)OC)=CC(OC)=C1NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 JSFKVAICWNSZMR-UHFFFAOYSA-N 0.000 description 1
- YDJRDWZLVGLVSJ-UHFFFAOYSA-N methyl 5-methoxy-4-nitro-2-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(OC)=C([N+]([O-])=O)C=C1C(F)(F)F YDJRDWZLVGLVSJ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WGHBKYWUOOANEX-UHFFFAOYSA-N n'-methyl-n'-phenylpropane-1,3-diamine Chemical compound NCCCN(C)C1=CC=CC=C1 WGHBKYWUOOANEX-UHFFFAOYSA-N 0.000 description 1
- QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical compound CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- CTCSYUDUFGKMSX-UHFFFAOYSA-N n,n-dimethyl-4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C=1C=CN=CC=1COC1=CC(C(=O)N(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 CTCSYUDUFGKMSX-UHFFFAOYSA-N 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- ZVRPTHOGPBFOKD-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound COC1=CC(C(=O)NC2C3CCN(CC3)C2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 ZVRPTHOGPBFOKD-UHFFFAOYSA-N 0.000 description 1
- FJPPQXSJIUDLRU-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound COC1=CC(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 FJPPQXSJIUDLRU-UHFFFAOYSA-N 0.000 description 1
- ABNJOBNEPRFCCF-UHFFFAOYSA-N n-(1-benzylpyrrolidin-3-yl)-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NC2CN(CC=3C=CC=CC=3)CC2)C=C1NC(=O)NC1=CN=CC=N1 ABNJOBNEPRFCCF-UHFFFAOYSA-N 0.000 description 1
- RRDZTKVGLQBBQM-UHFFFAOYSA-N n-(1h-benzimidazol-2-ylmethyl)-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCC=2NC3=CC=CC=C3N=2)=CC=C1NC(=O)NC1=CN=CC=N1 RRDZTKVGLQBBQM-UHFFFAOYSA-N 0.000 description 1
- UQUDXAPQGXQWJN-UHFFFAOYSA-N n-(1h-benzimidazol-2-ylmethyl)-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCC=2NC3=CC=CC=C3N=2)C=C1NC(=O)NC1=CN=CC=N1 UQUDXAPQGXQWJN-UHFFFAOYSA-N 0.000 description 1
- XUVMAOOIJJOPGR-UHFFFAOYSA-N n-(trifluoromethyl)pyrazin-2-amine Chemical compound FC(F)(F)NC1=CN=CC=N1 XUVMAOOIJJOPGR-UHFFFAOYSA-N 0.000 description 1
- IIIRORFSNKISHO-UHFFFAOYSA-N n-[(4-iodophenyl)methyl]-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCC=2C=CC(I)=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 IIIRORFSNKISHO-UHFFFAOYSA-N 0.000 description 1
- JECWVVQKPANEHX-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCC=2C3=CC=CC=C3NC=2)C=C1NC(=O)NC1=CN=CC=N1 JECWVVQKPANEHX-UHFFFAOYSA-N 0.000 description 1
- HODLXMRIAPRKJG-UHFFFAOYSA-N n-[2-(benzenesulfonyl)ethyl]-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCS(=O)(=O)C=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 HODLXMRIAPRKJG-UHFFFAOYSA-N 0.000 description 1
- KMZXJMWJWAVBCJ-UHFFFAOYSA-N n-[2-(benzenesulfonyl)ethyl]-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCS(=O)(=O)C=2C=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 KMZXJMWJWAVBCJ-UHFFFAOYSA-N 0.000 description 1
- HTPYHNZUUUMWKR-UHFFFAOYSA-N n-[2-(dimethylamino)-1-phenylethyl]-3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound COC1=CC(C(=O)NC(CN(C)C)C=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 HTPYHNZUUUMWKR-UHFFFAOYSA-N 0.000 description 1
- JSURWEBWHYTQBX-UHFFFAOYSA-N n-[2-(dimethylamino)-2-phenylethyl]-3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound COC1=CC(C(=O)NCC(N(C)C)C=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 JSURWEBWHYTQBX-UHFFFAOYSA-N 0.000 description 1
- GYRVOBULOXXJBW-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)NCCN(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 GYRVOBULOXXJBW-UHFFFAOYSA-N 0.000 description 1
- JWAUKAVHWZOCQF-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-methoxy-n-methyl-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)N(C)CCN(C)C)=CC=C1NC(=O)NC1=CN=CC=N1 JWAUKAVHWZOCQF-UHFFFAOYSA-N 0.000 description 1
- BDDAAMUETAVZAV-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C=1C=CN=CC=1COC1=CC(C(=O)NCCN(C)C)=CC=C1NC(=O)NC1=CN=C(C)C=N1 BDDAAMUETAVZAV-UHFFFAOYSA-N 0.000 description 1
- IMZKTRPDMPAXNG-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-methoxy-n-methyl-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)N(C)CCN(C)C)C=C1NC(=O)NC1=CN=CC=N1 IMZKTRPDMPAXNG-UHFFFAOYSA-N 0.000 description 1
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
- BPWYEHBVSQTEQD-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC(=O)NC1=CN=CC=N1 BPWYEHBVSQTEQD-UHFFFAOYSA-N 0.000 description 1
- CNNANRLBALGQKT-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-methoxy-n-methyl-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)N(C)CCCN(C)C)=CC=C1NC(=O)NC1=CN=CC=N1 CNNANRLBALGQKT-UHFFFAOYSA-N 0.000 description 1
- AABJTUMMGLXMHJ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCCCN(C)C)C=C1NC(=O)NC1=CN=CC=N1 AABJTUMMGLXMHJ-UHFFFAOYSA-N 0.000 description 1
- XEWHHZJDWLMJJH-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-methoxy-n-methyl-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)N(C)CCCN(C)C)C=C1NC(=O)NC1=CN=CC=N1 XEWHHZJDWLMJJH-UHFFFAOYSA-N 0.000 description 1
- HESFJPGEZWIMHN-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]-1-phenyl-4-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C(C(=C1)C(F)(F)F)=NN1C1=CC=CC=C1 HESFJPGEZWIMHN-UHFFFAOYSA-N 0.000 description 1
- HILLKXWKIRBMBS-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC(C=C1OC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 HILLKXWKIRBMBS-UHFFFAOYSA-N 0.000 description 1
- GEOIJPWCAKXLQM-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]acetamide Chemical compound COC1=CC(CNC(C)=O)=CC=C1NC(=O)NC1=CN=C(C)C=N1 GEOIJPWCAKXLQM-UHFFFAOYSA-N 0.000 description 1
- DGLAPQYONFZPJL-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]pyridine-2-carboxamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C1=CC=CC=N1 DGLAPQYONFZPJL-UHFFFAOYSA-N 0.000 description 1
- NTXDBRIYUFAYOF-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]pyridine-3-carboxamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C1=CC=CN=C1 NTXDBRIYUFAYOF-UHFFFAOYSA-N 0.000 description 1
- UCXLYJCVIYSPEN-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]pyridine-4-carboxamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C1=CC=NC=C1 UCXLYJCVIYSPEN-UHFFFAOYSA-N 0.000 description 1
- HSDFVBGXCAVLLR-UHFFFAOYSA-N n-[[3-methoxy-4-[(5-methylpyrazin-2-yl)carbamoylamino]phenyl]methyl]thiophene-2-carboxamide Chemical compound C=1C=C(NC(=O)NC=2N=CC(C)=NC=2)C(OC)=CC=1CNC(=O)C1=CC=CS1 HSDFVBGXCAVLLR-UHFFFAOYSA-N 0.000 description 1
- DNAWLMZFHMUKSX-UHFFFAOYSA-N n-benzyl-3-[3-(dimethylamino)propoxy]-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)NCC=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 DNAWLMZFHMUKSX-UHFFFAOYSA-N 0.000 description 1
- XQHJZJGEYWCINS-UHFFFAOYSA-N n-benzyl-3-[3-(dimethylamino)propoxy]-n-methyl-4-[(5-methylpyrazin-2-yl)carbamoylamino]benzamide Chemical compound CN(C)CCCOC1=CC(C(=O)N(C)CC=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=C(C)C=N1 XQHJZJGEYWCINS-UHFFFAOYSA-N 0.000 description 1
- FJWMYEQTZFSCHB-UHFFFAOYSA-N n-benzyl-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCC=2C=CC=CC=2)=CC=C1NC(=O)NC1=CN=CC=N1 FJWMYEQTZFSCHB-UHFFFAOYSA-N 0.000 description 1
- HGPWEBPCDHPMOG-UHFFFAOYSA-N n-benzyl-4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C1=NC(C)=CN=C1NC(=O)NC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1OCC1=CC=CN=C1 HGPWEBPCDHPMOG-UHFFFAOYSA-N 0.000 description 1
- QXNBBAWYPVZVPX-UHFFFAOYSA-N n-benzyl-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1NC(=O)NC1=CN=CC=N1 QXNBBAWYPVZVPX-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- KKXCMMIWHOYQCM-UHFFFAOYSA-N n-benzylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCC1=CC=CC=C1 KKXCMMIWHOYQCM-UHFFFAOYSA-N 0.000 description 1
- IRQVTJLZOFVQMG-UHFFFAOYSA-N n-butyl-3-methoxy-4-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound COC1=CC(C(=O)NCCCC)=CC=C1NC(=O)NC1=CN=CC=N1 IRQVTJLZOFVQMG-UHFFFAOYSA-N 0.000 description 1
- ZDNDXFLIWNVKRP-UHFFFAOYSA-N n-butyl-4-methoxy-3-(pyrazin-2-ylcarbamoylamino)benzamide Chemical compound CCCCNC(=O)C1=CC=C(OC)C(NC(=O)NC=2N=CC=NC=2)=C1 ZDNDXFLIWNVKRP-UHFFFAOYSA-N 0.000 description 1
- CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 1
- CAKXNQILBCOVLO-UHFFFAOYSA-N n-methyl-4-[(5-methylpyrazin-2-yl)carbamoylamino]-3-(pyridin-3-ylmethoxy)benzamide Chemical compound C=1C=CN=CC=1COC1=CC(C(=O)NC)=CC=C1NC(=O)NC1=CN=C(C)C=N1 CAKXNQILBCOVLO-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
- 229960004918 nimorazole Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229950010456 pimonidazole Drugs 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 1
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 1
- JQJOGAGLBDBMLU-UHFFFAOYSA-N pyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=N1 JQJOGAGLBDBMLU-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000000113 radiomimetic effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- CMIBWIAICVBURI-SSDOTTSWSA-N tert-butyl (3r)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](N)C1 CMIBWIAICVBURI-SSDOTTSWSA-N 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- MHFZANOEYACLLT-UHFFFAOYSA-N tert-butyl 3-[[4-methyl-2-[(5-methylpyrazin-2-yl)carbamoylamino]phenoxy]methyl]piperidine-1-carboxylate Chemical compound C=1N=C(C)C=NC=1NC(=O)NC1=CC(C)=CC=C1OCC1CCCN(C(=O)OC(C)(C)C)C1 MHFZANOEYACLLT-UHFFFAOYSA-N 0.000 description 1
- CITQBFZCHXEQCN-UHFFFAOYSA-N tert-butyl 3-amino-5-methylpyrazine-2-carboxylate Chemical compound CC1=CN=C(C(=O)OC(C)(C)C)C(N)=N1 CITQBFZCHXEQCN-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 1
- FPWNVMNGKNLYSC-UHFFFAOYSA-N tert-butyl n-[5-(bromomethyl)pyrazin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(CBr)C=N1 FPWNVMNGKNLYSC-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002341 thymus lymphoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
- C07D215/34—Carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27312401P | 2001-03-02 | 2001-03-02 | |
PCT/US2002/006452 WO2002070494A1 (en) | 2001-03-02 | 2002-03-01 | Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20033858D0 NO20033858D0 (no) | 2003-09-01 |
NO20033858L NO20033858L (no) | 2003-10-10 |
NO326776B1 true NO326776B1 (no) | 2009-02-16 |
Family
ID=23042649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20033858A NO326776B1 (no) | 2001-03-02 | 2003-09-01 | CHK1-inhibitorer, farmasoytiske sammensetninger samt anvendelser derav |
Country Status (28)
Country | Link |
---|---|
US (3) | US7067506B2 (pl) |
EP (1) | EP1379510B1 (pl) |
JP (1) | JP4222833B2 (pl) |
KR (2) | KR20080046228A (pl) |
CN (1) | CN100374425C (pl) |
AT (1) | ATE511503T1 (pl) |
AU (1) | AU2002258451B2 (pl) |
BR (1) | BR0207811A (pl) |
CA (1) | CA2439709C (pl) |
CY (1) | CY1111590T1 (pl) |
DK (1) | DK1379510T3 (pl) |
EA (1) | EA014954B1 (pl) |
ES (1) | ES2365504T3 (pl) |
GE (1) | GEP20053659B (pl) |
HK (1) | HK1062438A1 (pl) |
HR (1) | HRP20030688B1 (pl) |
IL (1) | IL157563A0 (pl) |
IS (1) | IS6935A (pl) |
MX (1) | MXPA03007920A (pl) |
NO (1) | NO326776B1 (pl) |
NZ (1) | NZ527787A (pl) |
PL (1) | PL212707B1 (pl) |
PT (1) | PT1379510E (pl) |
RS (1) | RS52077B (pl) |
SI (1) | SI1379510T1 (pl) |
UA (1) | UA76977C2 (pl) |
WO (1) | WO2002070494A1 (pl) |
ZA (1) | ZA200306721B (pl) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
US20060235035A1 (en) * | 2002-04-09 | 2006-10-19 | 7Tm Pharma A/S | Novel methoxybenzamibe compounds for use in mch receptor related disorders |
US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
US7056925B2 (en) | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
AU2003226929A1 (en) * | 2002-11-25 | 2004-06-18 | 7Tm Pharma A/S | Novel benzamide compounds for use in mch receptor related disorders |
JP3990718B2 (ja) | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
NZ562413A (en) * | 2003-02-21 | 2009-02-28 | Resmed Ltd | Headgear assembly for nasal pillows mask |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
US7320986B2 (en) | 2003-03-07 | 2008-01-22 | Abbott Labortories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
CA2526636C (en) | 2003-05-20 | 2012-10-02 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
AR045689A1 (es) * | 2003-05-29 | 2005-11-09 | Millennium Pharm Inc | Compuestos derivados de 2,5-dihidro-pirazolo[4,3-c]quinolin-4-ona como inhibidores de chk-1 y composiciones farmaceuticas que los contienen |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
EP1660474B1 (en) * | 2003-08-15 | 2008-10-29 | AstraZeneca AB | Substituted thiophenes and uses thereof |
US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2007504122A (ja) | 2003-08-29 | 2007-03-01 | ファイザー・インク | 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体 |
AU2004274013A1 (en) * | 2003-09-17 | 2005-03-31 | Icos Corporation | Use of Chk1 inhibitors to control cell proliferation |
CA2541949A1 (en) | 2003-10-07 | 2005-05-26 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
US20050096324A1 (en) * | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
CA2551324C (en) | 2004-01-06 | 2012-11-27 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
US20050176733A1 (en) * | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
MXPA06010904A (es) | 2004-03-24 | 2007-06-11 | Abbott Lab | Inhibidores de pirazol cinasa triciclicos. |
US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
US7625949B2 (en) | 2004-04-23 | 2009-12-01 | Roche Palo Alto Llc | Methods for treating retroviral infections |
US20050276765A1 (en) * | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
MX2007000259A (es) * | 2004-06-25 | 2007-07-20 | Icos Corp | Derivados de bisarilurea utiles para inhibir chk1. |
BRPI0512891A (pt) * | 2004-07-02 | 2008-04-15 | Icos Corp | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano |
WO2006021002A2 (en) * | 2004-08-19 | 2006-02-23 | Icos Corporation | Compounds useful for inhibiting chk1 |
DE102004055582A1 (de) | 2004-11-18 | 2006-05-24 | Bayer Cropscience Ag | N-Heterocyclyl-phthalsäurediamide |
JP2008523072A (ja) * | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
EP1828169A2 (en) * | 2004-12-07 | 2007-09-05 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
SI1869020T1 (sl) * | 2005-03-29 | 2011-02-28 | Icos Corp | Derivati heteroaril uree, ki so uporabni za inhibicijo chk1 |
BRPI0617720A2 (pt) | 2005-10-19 | 2011-08-02 | Hoffmann La Roche | compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
SMP200800041B (it) * | 2005-12-21 | 2009-07-14 | Novartis Ag | Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori |
CA2635888A1 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
CA2655857C (en) | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
EP1882475A1 (en) * | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
US9056136B2 (en) * | 2006-10-06 | 2015-06-16 | Natural Pharmacia International, Inc. | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia |
US8455471B2 (en) | 2006-10-20 | 2013-06-04 | Icos Corporation | Compositions of CHK1 inhibitors and cyclodextrin |
WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
WO2008140724A1 (en) | 2007-05-08 | 2008-11-20 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
US9000027B2 (en) * | 2008-02-04 | 2015-04-07 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3 |
ATE542813T1 (de) | 2008-08-06 | 2012-02-15 | Pfizer | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren |
US8314108B2 (en) | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
EP2241557A1 (de) * | 2009-04-02 | 2010-10-20 | Æterna Zentaris GmbH | Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen |
CN101857575A (zh) * | 2009-04-07 | 2010-10-13 | 上海合全药业有限公司 | 2-氨基-5-甲基吡嗪的工业化制备方法 |
CN101560175B (zh) * | 2009-05-08 | 2012-10-10 | 南京大学 | 一类硫脲类衍生物及其制备方法与用途 |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
EP2305643A1 (en) * | 2009-10-02 | 2011-04-06 | Ikerchem, S.L. | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
AR079529A1 (es) * | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
JP5585822B2 (ja) * | 2010-05-11 | 2014-09-10 | 東レ・ファインケミカル株式会社 | 光学活性ニペコチン酸誘導体の製造方法 |
GB201008005D0 (en) * | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
WO2012094297A1 (en) * | 2011-01-03 | 2012-07-12 | The Regents Of The University Of California | Azuvirin peptides |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
DK2751109T3 (en) | 2011-09-02 | 2017-01-23 | Incyte Holdings Corp | HETEROCYCLYLAMINES AS PI3K INHIBITORS |
GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
TWI748941B (zh) | 2015-02-27 | 2021-12-11 | 美商英塞特公司 | Pi3k抑制劑之鹽及製備方法 |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
BR112018005331A2 (pt) | 2015-09-17 | 2018-10-09 | Hope City | inibidores de pcna |
PL3411036T3 (pl) | 2016-02-04 | 2022-04-04 | Pharmaengine, Inc. | 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie |
CN106632093A (zh) * | 2016-11-23 | 2017-05-10 | 山东友帮生化科技有限公司 | 一种2‑溴‑5,6‑二苯基吡嗪的制备方法 |
MX2019011506A (es) | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
EP3806852A1 (en) | 2018-06-12 | 2021-04-21 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
US20210236466A1 (en) * | 2018-07-03 | 2021-08-05 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
GB201813060D0 (en) * | 2018-08-10 | 2018-09-26 | Artios Pharma Ltd | Novel compounds |
WO2020135210A1 (zh) * | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
CN111377874A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种制备赛乐西帕中间体的方法 |
CN114746413B (zh) | 2019-11-29 | 2024-02-23 | 南京明德新药研发有限公司 | 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用 |
WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
CN115353512A (zh) * | 2021-07-30 | 2022-11-18 | 上海翊石医药科技有限公司 | 一种杂环脲类化合物及其制备方法和用途 |
CN113717115A (zh) * | 2021-08-27 | 2021-11-30 | 湖北石河医药科技有限公司 | 一种赛乐西帕中间体的制备方法及其在制备赛乐西帕中的应用 |
WO2023172880A2 (en) * | 2022-03-07 | 2023-09-14 | City Of Hope | Pcna inhibitors and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2762743A (en) * | 1953-03-11 | 1956-09-11 | Merck & Co Inc | 1-phenyl-3(3-as-triazinyl) urea compositions for the treatment of coccidiosis and method for preparing the same |
US4609659A (en) * | 1985-01-16 | 1986-09-02 | Merck & Co., Inc. | 2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy |
US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US5041653A (en) * | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
SU1624949A1 (ru) | 1987-12-15 | 1996-02-27 | И.И. Красильников | м,N-БУТИРИЛАМИНОБЕНЗАМИД, ОБЛАДАЮЩИЙ РАДИОСЕНСИБИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
SU1621447A1 (ru) | 1989-06-29 | 1996-02-27 | О.В. Арапов | м,-(N-ТРИФТОРАЦЕТИЛАМИНО)БЕНЗАМИД, ОБЛАДАЮЩИЙ РАДИОСЕНСИБИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
US5212738A (en) * | 1991-04-12 | 1993-05-18 | Martin Marietta Magnesia Specialties Inc. | Scanning laser measurement system |
WO1993007128A1 (en) | 1991-10-11 | 1993-04-15 | The Du Pont Merck Pharmaceutical Company | Cyclic ureas and analogues useful as retroviral protease inhibitiors |
WO1994026715A1 (en) * | 1993-05-11 | 1994-11-24 | Smithkline Beecham Plc | Amidine derivatives as gastric acid secretion inhibitors |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
US6033582A (en) * | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6051218A (en) * | 1996-02-02 | 2000-04-18 | The Regents Of The University Of California | Tumor radiosensitization using gene therapy |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
WO1999011621A2 (en) * | 1997-09-03 | 1999-03-11 | American Home Products Corporation | Thiourea for increasing hdl-cholesterol levels, which are useful as anti-atherosclerotic agents |
US6218109B1 (en) * | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
AU2160899A (en) * | 1997-12-11 | 1999-06-28 | Janssen Pharmaceutica N.V. | Retinoic acid mimetic anilides |
EP1054004B1 (en) | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
ES2153809T3 (es) | 1997-12-22 | 2005-07-16 | Bayer Pharmaceuticals Corporation | Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente. |
CA2315715C (en) | 1997-12-22 | 2010-06-22 | Bayer Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
AU1529799A (en) * | 1997-12-23 | 1999-07-12 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
US6383744B1 (en) | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
RU2219171C2 (ru) * | 1998-09-25 | 2003-12-20 | Астразенека Аб | Производные амида, способ их получения и фармацевтическая композиция на их основе |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
FR2787322B1 (fr) | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
AU3631500A (en) * | 1999-03-19 | 2000-10-09 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
ES2251395T3 (es) | 1999-07-26 | 2006-05-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de biarilureas. |
US6670167B1 (en) | 1999-11-01 | 2003-12-30 | Agouron Pharmaceuticals, Inc. | Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof |
JP2003522174A (ja) | 2000-02-07 | 2003-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼの3−アミノピラゾール阻害剤 |
US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
-
2002
- 2002-01-03 UA UA2003098173A patent/UA76977C2/uk unknown
- 2002-03-01 AT AT02728396T patent/ATE511503T1/de active
- 2002-03-01 PT PT02728396T patent/PT1379510E/pt unknown
- 2002-03-01 EA EA200300947A patent/EA014954B1/ru not_active IP Right Cessation
- 2002-03-01 RS YU69003A patent/RS52077B/sr unknown
- 2002-03-01 JP JP2002569814A patent/JP4222833B2/ja not_active Expired - Fee Related
- 2002-03-01 US US10/087,715 patent/US7067506B2/en not_active Expired - Fee Related
- 2002-03-01 CA CA2439709A patent/CA2439709C/en not_active Expired - Fee Related
- 2002-03-01 EP EP02728396A patent/EP1379510B1/en not_active Expired - Lifetime
- 2002-03-01 BR BR0207811-2A patent/BR0207811A/pt not_active IP Right Cessation
- 2002-03-01 IL IL15756302A patent/IL157563A0/xx unknown
- 2002-03-01 AU AU2002258451A patent/AU2002258451B2/en not_active Ceased
- 2002-03-01 KR KR1020087008269A patent/KR20080046228A/ko not_active Application Discontinuation
- 2002-03-01 GE GE5316A patent/GEP20053659B/en unknown
- 2002-03-01 CN CNB028093216A patent/CN100374425C/zh not_active Expired - Fee Related
- 2002-03-01 DK DK02728396.9T patent/DK1379510T3/da active
- 2002-03-01 NZ NZ527787A patent/NZ527787A/en not_active IP Right Cessation
- 2002-03-01 WO PCT/US2002/006452 patent/WO2002070494A1/en active Application Filing
- 2002-03-01 MX MXPA03007920A patent/MXPA03007920A/es active IP Right Grant
- 2002-03-01 KR KR1020037011393A patent/KR100861829B1/ko not_active IP Right Cessation
- 2002-03-01 PL PL364564A patent/PL212707B1/pl unknown
- 2002-03-01 SI SI200230957T patent/SI1379510T1/sl unknown
- 2002-03-01 ES ES02728396T patent/ES2365504T3/es not_active Expired - Lifetime
-
2003
- 2003-08-28 ZA ZA200306721A patent/ZA200306721B/en unknown
- 2003-08-28 HR HRP20030688AA patent/HRP20030688B1/hr not_active IP Right Cessation
- 2003-08-29 IS IS6935A patent/IS6935A/is unknown
- 2003-09-01 NO NO20033858A patent/NO326776B1/no not_active IP Right Cessation
-
2004
- 2004-07-12 HK HK04105049.6A patent/HK1062438A1/xx not_active IP Right Cessation
-
2005
- 2005-04-27 US US11/115,993 patent/US7608618B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/551,623 patent/US20100105683A1/en not_active Abandoned
-
2011
- 2011-06-24 CY CY20111100602T patent/CY1111590T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO326776B1 (no) | CHK1-inhibitorer, farmasoytiske sammensetninger samt anvendelser derav | |
AU2002258451A1 (en) | Aryl and Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chemosensitizers | |
US7560462B2 (en) | Compounds useful for inhibiting CHK1 | |
US20150353538A1 (en) | Compounds and therapeutic uses thereof | |
CA2602199C (en) | Heteroaryl urea derivatives useful for inhibiting chk1 | |
US20080318974A1 (en) | Compounds Useful for Inhibiting Chk1 | |
JP2008535830A5 (pl) | ||
CA2571424A1 (en) | Bisarylurea derivatives useful for inhibiting chk1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
MM1K | Lapsed by not paying the annual fees |